CLOVERS Protocol Version VIII  
February 17, 2021   
Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis  
 
ACRONYM :  CLOVERS  
VERSION   VIII 
PROTOCOL CO -CHAIRS   
IVOR DOUGLAS , MD 
NATHAN I. SHAPI[INVESTIGATOR_274317] , MD,  MPH  
 
 
 P
ROTOCOL COMMITTEE            ADVISORS TO PROTOCOL  
Roy G Brower, MD                Rinaldo Bellomo, MD 
Samuel M. Brown, MD               Stephen Macdonald, MD  
Ben P deBoisblanc, MD                
Matthew C Exline, MD        
Adit A. Ginde, MD         
Colin K Grissom, MD                 
Doug Hayden PhD  
Alan E. Jones, MD  
Kathleen Liu, MD  
Chadwick D Miller, MD  
Katie Oldmixon, RN  
Pauline K Park, MD  
Lora Reineck, MD  
Todd W Rice, MD  
Nancy Ringwood, BSN  
Wesley H. Self, MD Matthew Semler, MD  
Jay S Steingrub, MD  
Daniel Talmor, MD  
B. Taylor Thompson, MD  
Donald M. Yealy, MD  
 
  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        2 
 Table of Contents  
1. Abbreviations and Definitions ............................................................................................................... 6  
1.1 Abbreviations  ................................................................................................................................ 6  
1.2 Definitions  ..................................................................................................................................... 7  
2. Trial Summary  ....................................................................................................................................... 9  
2.1 Title  ............................................................................................................................................... 9  
2.2 Objective  ....................................................................................................................................... 9  
2.3 Hypothesis  ..................................................................................................................................... 9  
2.4 Study Design .................................................................................................................................. 9  
2.5 Inclusion Criteria  ......................................................................................................................... 10 
2.6 Exclusion Criteria  ......................................................................................................................... 10 
2.7 Random ization and Initiation Time Window  .............................................................................. 11 
2.8 Primary Endpoint  ........................................................................................................................ 11 
2.9 Secondary Endpoints  .................................................................................................................. 11 
2.10  Process of Care Metrics  .............................................................................................................. 12 
2.11  Sample Size/Interim Monitoring  ................................................................................................. 12 
3. Trial Description  .................................................................................................................................. 12 
3.1 Background  ................................................................................................................................. 12 
3.2 Rat
ionale for Liberal Fluid Approach  .......................................................................................... 13 
3.3 Rationale for Restrictive Fluids Approach  ................................................................................... 14 
3.4 Equipoise Exists Between Liberal and Restrictive Fluid Approaches?  ........................................ 15 
3.5 Objectives .................................................................................................................................... 15 
3.6 Endpoints  .................................................................................................................................... 16 
3.6.1 Primary Outcome  ....................................................................................................................... 16 
3.6.2 Second ary Outcomes  ................................................................................................................. 16 
3.6.3 Process of Care Metrics  ............................................................................................................. 18 
3.6
.4 Subgroups for secondary analysis  .............................................................................................. 19 
4. Study Population and Enrollment  ....................................................................................................... 20 
4.1 Number/Source Screening .......................................................................................................... 20 
4.2 Inclusion Criteria  ......................................................................................................................... 20 
4.3 Exclusion Criteria  ......................................................................................................................... 20 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        3 
 4.4 Reasons for Exclusions  ................................................................................................................ 21 
4.5 Randomization and Study Initiation Time Window  .................................................................... 21 
4.6 Screening Log  .............................................................................................................................. 21 
4.7 Randomization  ............................................................................................................................ 22 
4.8 Minorities and Women  ............................................................................................................... 22 
5. Study  Procedures  ................................................................................................................................ 22 
5.1 Restrictive Fluids Group (Early Vasopressors)  ............................................................................ 22 
5.2 Liberal Fluids Group .................................................................................................................... 23 
5.3 The Use of Cardiac Ultrasound and Other Hemodynamic Monitoring Techniques  ................... 25 
6. Duration of the Protocol  ..................................................................................................................... 25 
6.1 Common Strategies for Both Study Groups  ................................................................................ 25 
6.1.1  Permitted Fluid Types  ......................................................................................................... 25 
6.1.2  Antibiotics  ........................................................................................................................... 25 
6.1.3  Ventilator Procedures  ......................................................................................................... 25 
6.1.4  Vasopressor Use  .................................................................................................................. 26 
6.1.5  Fluid management After Protoco l Conclusion (post 24 hours)  .......................................... [ADDRESS_335376] of Change in Fluid Protocol on Outcome  .......................................................................... 34 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        4 
 10. Data Collection and Monitoring ...................................................................................................... 35 
11. Risk Assessment  .............................................................................................................................. 35 
11.1  Potential Risks to Subjects  .......................................................................................................... 35 
11.2  Risk of Death  ............................................................................................................................... 36 
11.3  Minimization of Risk  .................................................................................................................... 36 
11.4  Potential Benefits  ........................................................................................................................ 36 
11.5  Risks in Relation to Anticipated Benefits  .................................................................................... 37 
12. Human Subjects  .............................................................................................................................. 37 
12.1.  Selection of Subjects  ............................................................................................................... 37 
12.2.  Justification for Including Vulnerable Subjects  ....................................................................... 37 
12.3.  Informed Consent  ................................................................................................................... 37 
12.4.  Cont inuing Consent  ................................................................................................................. 40 
12.5.  Withdrawal of Consent  ........................................................................................................... 40 
12.6.  Identification of Legally Authorized Representatives  ............................................................. 40 
12.7.  Justification of Surrogate Consent  .......................................................................................... 41 
12.8.  Additional Safeguards for Vulnerable Subjects  ...................................................................... 42 
12.9.  Confidentiality  ......................................................................................................................... 42 
13. Adverse Events  ................................................................................................................................ 42 
13.1  Safety Monitoring  ................................................................................................................... 42 
13.2  Se
rious Adverse Events  ............................................................................................................... 43 
Appendices  .................................................................................................................................................. 45 
A. Protocol Schema  ............................................................................................................................. 45 
A.1 Liberal Protocol (follow for 24 hours)  ........................................................................................... 46 
A.2 Restrictive Protocol (follow for 24 hours)  .................................................................................... [ADDRESS_335377]  ................................................................................................. 48 
C. SOFA Scoring System ...................................................................................................................... 49 
D. Ventilator Weaning  ......................................................................................................................... 50 
E. Vasopressor Weaning  ..................................................................................................................... 52 
F. Tim
e Events Schedule  ..................................................................................................................... 53 
G. Adverse Event Reporting and Unanticipated Events  ...................................................................... 54 
G1.  Unanticipated problems (UP)  ...................................................................................................... 54 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        5 
 G2.  Determining relationship of adverse events to procedures  ........................................................ 54 
G3.  Clinical outcomes that may be exempt from adverse event reporting ....................................... 55 
G4.  Decision tree for determining if an adverse event is reportable  ................................................ 56 
H. Imputed P/F using SpO2 and FiO2  .................................................................................................. 57 
I. Language Cassettes Related to Provider Treatment Preference for the  ........................................ 58 
J. SHAMROC Study Protocol  ............................................................................................................... 60 
References  .................................................................................................................................................. 70 
 
 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        6 
 1. Abbreviations and Definitions  
1.1 Abbreviations  
ARDS  = Acute Respi[INVESTIGATOR_274318]  = Bilevel Positive Airway Pressure  
BUN = Blood Urea Nitrogen 
CCC = Clinical Coordinating Center  
DSMB = Data Safety Monitoring Board  
FACTT = Fluid and Catheter Treatment 
Trial 
FiO 2 = Fraction of Inspi[INVESTIGATOR_274319]  = Glasgow Coma Scale 
ICU = Intensive Care Unit 
IL-6 = Interleukin 6  
IL-8 = Interleukin 8  
INR = International Normalized Ratio 
ITT = Intent to Treat  
KDIGO  = Kidney Disease Improving Global 
Outcomes  
LAR=Legally Authorized Representative 
NHLBI  = National Heart Lung and Blood 
Institute  
PETAL = Prevention and Early Treatment 
of Acute Lung Injury   
P/F = PaO 2/FiO 2 ratio 
S/F = SpO 2/FiO 2 ratio 
SOFA = Sequential Organ Failure 
Assessment  
 
 
 
SBP = Systolic Blood Pressure  
SpO 2 = Oxygen Saturation via pulse 
oximetry  
S[LOCATION_003]R =  Serious and Unexpected 
Suspected Adverse Reactions  
SAEs=  Serious Adverse Events  
VFD = Ventilator -free Days  
WBC = White Blood Cell  count  
 
CLOVERS Protocol Version VIII  
February 17, 2021  1.2 Definitions  
 
Adverse Event:  Any untoward medical occurrence associated with the use of a drug or a study 
procedure, whether or not considered drug related.  
Adverse reaction:  An adverse reaction means any adverse event caused by a study 
intervention.  An adverse reaction is a subset of all suspected adverse reactions where there is 
a reason to conclude that the study intervention caused the event.  
Assisted Ventilation (or Assisted Breathing):  any level of ventilatory support at pressures 
higher than the unassisted breathing thresholds .  
Home : Level of residence or health care facility where the patient was residing prior to hospi[INVESTIGATOR_15517].  
Intention to Treat (ITT):   All eligible and consented patients who undergo randomization will be 
included in the ITT cohort for the purposes of analyzing the primary and secondary study outcomes.  
Invasive Mechanical Ventilation: Assisted ventilation delivered by a nasotracheal, orotracheal, or tracheostomy tube.   
Legal ly Authorized Representative: An individual, judicial, or other body authorized under 
applicable law to consent on behalf of a prospective patient to the patient's participation in the 
clinical study. 
Mortality prior to discharge home before day 90: This primary outcome includes deaths from 
all causes following randomization in any heath care facility prior to discharge home until study 
day 90. Study subjects still in a health care facility at study day 91 are considered alive for this 
endpoint.  
Funding: National Institutes of Health (National Heart Lung and Blood Institute) 
SAEs:  Serious Adverse Events Adverse events that are serious and unexpected and have a 
reasonable possibility that the event was due to a study procedure   
Sponsor:  The Clinical Coordinating Center at [LOCATION_005] General Hospi[INVESTIGATOR_274320]: The day of randomization is study day zero. The next day is study day one etc.  
Study hospi[INVESTIGATOR_307] : Defined as the hospi[INVESTIGATOR_274321].  
Study withdrawal : Defined as permanent withdrawal from study before completion of study 
activities. If a patie nt or surrogate requests withdrawal from the study the clinician should seek 
explicit permission to continue data collection.  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        8 
 Suspected adverse reaction : any adverse event for which there is a reasonable possibility that 
the study procedures caused the adverse event.  Reasonable possibility means there is 
evidence to suggest a causal relationship between the study procedures and the adverse event.  
A suspected adverse reaction implies a lesser degree of certainty about causality than adverse 
reaction (21 CFR 312.32(a)).  
Suspected Unexpected Serious Adverse Reaction  (S[LOCATION_003]R ) An adverse reaction that is both 
unexpected (not consistent with the risks outlined in the protocol or investigator brochure), serious, and meets the definition of a Suspected Adverse Reaction 
UAB (Unassisted Breathing): Spontaneously breathing with face mask, nasal prong oxygen, 
room air, T- tube breathing, tracheostomy mask breathing, CPAP ≤ 5 without PS or IMV 
assistance, or the use of noninvasive ventilation solely for sleep- disordered breathing 
  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        9 
 2. Trial Summary  
2.1 Title 
Crystalloids Liberal Or Vasopressors Early Resuscitation in Sepsis (CLOVERS)  
2.2 Objective  
Primary Objective:  To determine the impact of a restrictive fluids  strategy (vasopressors first 
followed by [CONTACT_274386]) as compared to a liberal fluid strategy (fluids first followed by [CONTACT_274387]) on 90 -day in- hospi[INVESTIGATOR_274322] -induced hypotension.  
2.3 Hypothesis  
Primary Hypothesis: Restrictive (vs liberal) fluid treatment strategy during the first 24 hours of 
resuscitation for sepsis -induced hypotension will reduce 90 -day in -hospi[INVESTIGATOR_34380].     
2.4 Study Design  
Study Design: Multicenter, prospective, phase [ADDRESS_335378] 24 hours for patients with sepsis -induced hypotension.   
 
1. We will emphasize early screening and protocol initiation, and enroll a maximum of 2320 
patients with suspected sepsis -induced hypotension. 
 All patients will receive at least 1 liter of fluids prior to meeting study inclusion criteria 
(and no more than 3 liters prior to randomization ). 
 Patients will be enrolled within 4 hours of meeting study inclusion criteria  
 Balanced crystalloid solution (such as lactated Ringers, Hartman’s solution, 
Plasmalyte or Normosol)  recommended  
 
2. Restrictive Fluids ( Early Vasopressors) Group (See Protocol Schema Appendix A)  
 Norepi[INVESTIGATOR_274323] (MAP) between 65 mmHg and 75 mmHg  
 “Rescue fluids” recommended as 500  ml boluses if predefined rescue criteria are 
met 
   
3. Liberal Fluids (Fluids First) Group (See Protocol Schema Appendix A)  
 Additional 2-liter intravenous fluid infusion  upon enrollment  with a clinical evaluation 
at the end of the first liter  
 Administer 500 ml fluid boluses for fluid triggers until 5 liters administered (includes 
BOTH pre-randomization and post -randomization intravenous fluids), or 
development of clinical signs of acute volume overload develop  
 Return to  care without study guidance after 5 liters of fluid  (this includes BOTH pre-
randomization and post -randomization intravenous fluids) are administered 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        10 
 “Rescue vasopressors” recommended for persistent hypotension/hypoperfusion and 
acute volume overload,  if other “rescue ” criteria are met , or if the judgment of the 
clinical team is that vasopressors are thought to be in the best interest of the 
patient during fluid administration to support blood pressure and then weaned off 
as feasible once the fluid boluses have had their effect.  
 
4. Attending physician and clinical provider oversight  
 The attending physician must agree that both the CLOVERS Early Vasopressor 
and Fluid First approaches are consistent with good medical care for their 
patient prior to enrollment.   
 The attending physician will be informed that fluids or vasopressors can be used 
at any time if they are thought to be in the best interest of the patient.  
 
5. Other care 
 Other elements of care (e.g. antibiotics, ventilation strategies, etc.) will be 
recommended  to reflect current “best -practice” where feasible and appropriate  
2.5 Inclusion Criteria  
1. Age ≥ 18 years  
2. A suspected or confirmed infection (broadly defined as administration or planned 
administration of antibiotics)  
3. Sepsis -induced hypotension defined as systolic blood pressure < 100 mmHg or MAP < 
[ADDRESS_335379] 1 liter of fluid 
(*Fluids inclusive of pre -hospi[INVESTIGATOR_274324]; blood pressure must be below any known or 
reported pre- morbid baseline).  
2.6 Exclusion Criteria  
1. More than 4 hours elapsed since meeting inclusion criteria 
2. More than 24 hours elapsed since presentation to the hospi[INVESTIGATOR_307]  
3. Patient already received more than 3 liters of intravenous fluid (includes prehospi[INVESTIGATOR_274325])  
4. Unable to obtain informed consent   
5. Pregnancy  
6. Hypotension suspected to be due to non- sepsis cause (e.g.  hemorrhagic shock)  
7. Blood pressure is at known or reported baseline level  
8. Severe Volume Depletion from an acute condition other than sepsis.  
In the judgment of the treating physician, the patient has an acute condition other than 
sepsis causing (or indicative) of *severe volume depletion; 
Examples include: Diabetic ketoacidosis, high volume vomiting or diarrhea, 
hypersomolar hyperglycemic state, and nonexertional hyperthermia (heat stroke); severe 
is defined by [CONTACT_274388] 17, 2021                                                                                                                                                        11 
 9. Pulmonary edema or clinical signs of new fluid overload (e.g. bilateral crackles, new 
oxygen requirement, new peripheral edema, fluid overload on chest x -ray) 
10. Treating physician unwilling to give additional fluids as directed by [CONTACT_274389] * 
11. Treating physician unwilling to use vasopressors as directed by [CONTACT_274390] *.  
12. Current or imminent decision to withhold most/all life- sustaining treatment; this does not  
exclude those patients committed to full support except cardiopulmonary resuscitation 
13. Immediate surgical intervention planned such that study procedures could not be  
followed  
14. Patient no longer meets the hypotension inclusion criterion (no available SBP < 100 or 
MAP < 65 within 30 minutes of randomization or not receiving a vasopressor infusion ) 
15. Prior enrollment in this study   
*Patients will be excluded i f the attending physicians believes that either study arm is not 
good clinical care for his/her patient in their clinical judgement (see Appendix I)  
 
2.[ADDRESS_335380], or ICU.  
2.8 Primary Endpoint  
The primary outcome is all -cause mortality prior to discharge home before day 90.  
2.9 Secondary Endpoints 
1. 28-day organ support free days (alive and without mechanical ventilation, new renal 
replacement or vasopressors; vasopressors prior to 48 hours excluded)  
2. 28-day ventilator free days  
3. 28-day renal replacement free days (new renal replacement therapy)  
4. 28-day vasopressor free days (vasopressors prior to 48 hours excluded)  
5. 28-day ICU free days  
6. 28-day hospi[INVESTIGATOR_274326]  
7. Initiation of mechanical ventilation to day 28  
8. Initiation of renal replacement therapy  to day 28  
9. Change in creatinine- based KDIGO stage between baseline and 72 hours  
10. Change in SOFA score between baseline and 72 hours  
11. 90-day all -cause mortality  
12. Development of ARDS within 7 days  
13. Change in Interleukin- 6 (IL-6) levels  
14. New onset atrial or ventricular arrhythmia to day 28  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        12 
 2.10 Process of Care Metrics 
Process of Care Metrics: We w ill assess whether the proposed intervention has effectively 
altered care as intended  by [CONTACT_35755]:  
 Total intravenous fluids administered over initial 6 hours  
 Total intravenous fluids administered over initial 24 hours  
 Proportion receiving vasopressors and timing of vasopressor initiation within 24- hour 
study period  
 Total fluids administered prior to initiation of vasopressors   
2.11 Sample Size/Interim Monitoring  
1. Randomization 1:1; two- sided alpha 0.[ADDRESS_335381] a 4.5% absolute mortality difference 
between treatment groups with 90% power assuming 15% mortality in the liberal fluids 
group. The principal analysis will be intent -to-treat, based upon randomization 
assignment.  
2. There will be a protocol feasibility assessment phase at the approximately100- patient  
mark , and then after approximately  100 enrolled patients are available after any protocol 
changes for 2 more evaluation assessments.  Aggregate data blinded to outcomes will be used to assess patient accrual, treatment protocol compliance, and separation of 
intravenous fluid and/or vasopressor administration. Protocol adjustments may be made at each of these patient marks to optimize the protocol.  The study may be halted during 
the feasibility assessment phase for failure to meet pre- specified stoppi[INVESTIGATOR_15381]  
3. Trial progress will be evaluated by [CONTACT_274391] 
(DSMB) to determine whether  the study s hould stop for superiority of either the liberal or 
restrictive fluid strategies; or, for projected trial futility. (See Appendix B) There will be 
two interim analyses and a final analysis conducted when approximately each 
successive 1/[ADDRESS_335382] been enrolled. 
3. Trial Description  
3.1 Background  
Fluid resuscitation is a cornerstone for initial treatment of patients with sepsis -induced 
hypotension or septic shock [1].  In a [ADDRESS_335383]. Emmanuel Rivers et al[2]  
demonstrated that early identification and aggressive resuscitation of septic shock patients, as 
delivered through the Early Goad Directed Therapy (EGDT) algorithm, led to a substantial 
mortality reduction as compared to “usual care” at that time.  This trial broadly led to a re-
examination of clinical practice and is considered to have facilitated a more timely, aggressive, and compulsive approach to sepsis care.  More recently, t hree large  trials of Early Goal Directed 
Therapy  (ProCESS[3] , ARISE[4] , and ProMISe[5] ) demonstrated resuscitation targeting 
physiologic endpoints (central venous pressure (CVP), saturation of mixed venous oxygen 
(SvO
2), and mean arterial pressure (MAP)) was not superior t o current usual care.  Most 
patients in both the intervention and control groups of these trials received early sepsis 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        13 
 identification, prompt antibiotics, and large fluid boluses early in the res uscitation. [3-5] 
Furthermore, mortality in both the intervention and control groups was lower than historical 
septic shock mortality rates, leading many readers to conclude that advances in usual care for 
sepsis since the original Rivers trial led to improved outcomes over time. [6] However, the 
contribution of large volume fluid resuscitation toward declining sepsis mortality is unclear, and 
the optimal use of intravenous (IV) fluids and vasopressors remains controversial, with some 
advocating for liberal use of fluids to maintain blood pressure[2, 7 -9] and others advocating for 
more restrictive use of fluids and relying on vasopressors to maintain blood pressure. [10, 11]  
Currently, no high quality data exist to guide clinical decision making on the volume of fluid to administer during early septic shock resuscitation. Equipoise clearly exists. This trial will directly 
compare early sepsis resuscitation with large IV volumes coupled with rescue vasopressors as 
opposed to  early vasopressors coupled with rescue fluids.  
3.2 Rationale for Liberal Fluid Approach  
A “liberal” fluid approach to septic shock management is characterized by [CONTACT_274392] (> 30 ml/kg) of IV crystalloid to an adult during the initial resuscitation period and assumes intravascular  volume expansion is more beneficial than other potential treatment 
approaches for hypotension.  Vasopressor medications are added if the patient is profoundly hypotensive ( e.g. a systolic blood pressure < 70 mmHg) or remains hypotensive despi[INVESTIGATOR_274327].  This liberal fluid approach is the predominant  strategy used in U.S. 
emergency departments, and has been encouraged by [CONTACT_274393] [1], advocates of Early Goal Directed Therapy [2, 7, 8] , and the National Quality 
Forum Severe Sepsis and Septic Shock Management Bundle (NQF #0500) [9], which has been 
endorsed by [CONTACT_274394] (CMS) as the SEP -1 core 
measure. [12]   
The physiologic rationale for liberal fluid administration is based on the notion that septic shock 
causes loss of vasomotor  tone and intravascular volume depletion from loss of fluid into the 
extravascular space via leaky capi[INVESTIGATOR_11037]. [12] Crystalloid administration bolsters fluid volume 
within dilate d vessels and replaces fluid lost into the extravascular space, potentially increasing 
cardiac pre- load, stroke volume, and cardiac output, thereby  [CONTACT_274395].  Reversal of hypotension with fluid boluses allows clinicians to avoid vasopressors, which have the potential to cause  cardiac arrhythmias, tissue ischemia, and soft 
tissue damage from extravasation. [13]   
Several clinical studies during the past two decades have suggested that large volume fluid resuscitation is associated with improved outcomes for patients with septic shock.  In the 1990s, in-hospi[INVESTIGATOR_274328] 40% -50% range for 
hospi[INVESTIGATOR_274329].[8]  In 2001, Rivers et al. [2] published results of a single- center 
trial showing lower in -hospi[INVESTIGATOR_274330], a protocolized 
resuscitation strategy targeting CVP, SvO
2 and MAP, compared to usual sepsis resuscitation at 
the time (mortality: 30.5% vs 46.5%). The Early Goal Directed Therapy protocol included instructions to administer IV fluid boluses to achieve a CVP > [ADDRESS_335384] six hours of 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        14 
 treatment than those in the usual care control group (mean volume of IV fluid administration: 5.0 
liters vs 3.5 liters).[2]  Following this trial, the practice of early large- volume fluid resuscitation 
was widely adopted. [14] Observational studies at many institutions during the past 15 years 
demonstrated that efforts to implement Early Goal Directed Therapy protocols – even if full 
protocol adherence was incomplete and low - were associated with larger volumes of fluid 
administration and lower mortality.[8]   However, most of these studies involved implementation 
of a multifaceted bundle of sepsis care, had varying and low compliance with specific aspects of 
the protocol, and the effects of different volumes of fluid resuscitation were not separated from 
the effects of other bundle components, such as routine lactate measurement, early antibiotics, 
and specialized sepsis response teams. [15, 16]  
Results of three large multicenter trials evaluating Early Goal Directed Therapy for early septic 
shock resuscitation, including ProCESS [3], ARISE [4], and P roMISe [5], published in 2014- 2015 
demonstrated no significant difference in mortality between patients initially resuscitated according to Early Goal Directed Therapy versus usual care.  The volume of intravenous fluid administration during the initial 6 hours of treatment in the Early Goal Directed Therapy group 
was only slightly larger than the usual care group in each of these trials (mean fluid volume: 
approximately 4.3 – 5.3 liters in all groups of all trials), indicating that early, large volume fluid 
resuscit ation had been incorporated into usual care.  Therefore, the ProCESS, ARISE, and 
ProMISe trials did not directly provide data on the comparative effects of a liberal versus 
restrictive fluid strategy or give precise guidance on an optimal dose of IV fluids . However, these 
trials did demonstrate that the short -term mortality risk for patients with septic shock today 
(approximately 18% – 25%) declined compared to the 1990s (approximately 40% - 50%), a 
period during which early large volume fluid resuscitation was not routine. These data suggest 
the possibility, though not directly proven, that a more liberal early fluid strategy may have 
contributed to declining sepsis mortality over time.  
3.3 Rationale for Restrictive Fluids Approach  
A “restrictive” fluid approach to septic shock management is characterized by [CONTACT_274396] (< 20 ml/kg) to reverse overt intravascular volume depletion coupled 
with the use of vasopressors early in the resuscitation. The primary strategy to maintain blood 
pressure and systemic perfusion is vasopressor titration, with fluid boluses used to augment vasopressor therapy when signs of tissue hypoperfusion persist despi[INVESTIGATOR_274331], such as norepi[INVESTIGATOR_238] >20 mcg/min (0.25 mcg/kg/min in an 80 kg adult).  Historically, 
the common practice of requiring central venous access for vasopressor infusion hampered 
vasopressor use early in care. [17] However, emerging data suggest norepi[INVESTIGATOR_274332], [18, 19]  which facilitates 
vasopressor use as a viable option for early sepsis resuscitation.  
The physiologic rationale for a restrictive fluid strategy notes that IV crystalloid administration 
transiently increases intravascular volume but also leads to worsening extravascular fluid leakage (edema). The latter may interfere with cellular function in the kidneys, liver, heart and lungs.[11]  Several days of diuresis after shock resolution are often necessary to remove this 
excess fluid generated by [CONTACT_274397].[20]  Meanwhile, vasopressors can 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        15 
 reverse the loss of vasomotor tone and increase cardiac output without burdening tissues with 
excess extravascular fluid. [21]  Physiologic studies suggest that 30-50% of septic shock 
patients do not have an increase in cardiac output with fluid boluses; and, when cardiac output 
does increase, it often  only lasts for 30- 60 minutes. [11, 22 -24] Therefore, many septic patients 
treate d aggressively with fluids potentially experience little benefit in terms of increased cardiac 
output but do experience significant negative consequences from tissue edema.  Increased 
CVP from fluid boluses may actually decrease tissue perfusion by [CONTACT_274398], which drives tissue perfusion. [25] 
Furthermore, some have hypothesized that the peripheral vasoconstrictive response to shock is 
beneficial by [CONTACT_274399]- vital 
tissues; rapid reversal of this adaptive physiologic response with fluid boluses may be 
deleterious.   
More recent clinical studies suggest that large fluid boluses as an initial therapy for septic shock 
may have deleterious effects on patient outcomes.  Maitland et al. [26] published the FEAST 
study in 2011. In this trial conducted in sub -Saharan Africa, septic children randomized to initial 
therapy with IV crystalloid boluses had higher 48 -hour mortality than those treated without fluid 
boluses (10.5% vs 7.3%).  While results of this trial that included young children (median age 2 
years) who were predominately infected with malaria are not directly generalizable to adults in U.S. emergency departments and ICUs, these data do challenge the paradigm that large 
volume fluid resuscitation is universally beneficial to septic patients. In the recently -published 
CLASSIC trial of 151 adults with septic shock, Hjortrup et al[10]
 found that after an initial fluid 
bolus of ≥ 30 ml/kg, a restrictive fluid strategy was associated with less total fluid volume 
administered and lower risk of acute kidney injury than a usual care liberal fluids strategy; mortality was not statistically different between groups in that small trial.  
3.4 Equipoise Exists Between Liberal and Restrictive Fluid Approaches?  
Despi[INVESTIGATOR_274333], morbidity and mortality from septic 
shock remain high, with opportunity for additional improvement.[14, 3- 5] Although large volume 
fluid boluses are commonly used during the initial resuscitative phase of septic shock 
management, this practice is based on low quality evidence.[14, 11]  Challenging the liberal fluid 
strategy is appropriate at this time because patient outcomes remain suboptimal, and there is 
strong physiologic rationale for a res trictive fluid, vasopressor -centered strategy.[11, 20- 22, 24, 
23, 25]  While recent clinical studies suggest a restrictive strategy may be superior to a liberal 
strategy, [10, 26] no large, rigorous trial has compared these approaches. Theref ore, we will 
conduct a phase III randomized controlled trial comparing all -cause 90- day in-patient mortality 
with a liberal versus restrictive fluid approach for early management of sepsis -induced 
hypotension.  
3.5 Objectives  
Primary Objective: To determine the impact of a restrictive fluids strategy (vasopressors first 
followed by [CONTACT_274386]) as compared to a liberal fluid strategy (fluids first followed by [CONTACT_274387]) on 90 -day in- hospi[INVESTIGATOR_274322] -induced hypotension.  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        16 
 Primary Hypothesis: Restrictive (vs liberal) fluid treatment strategy during the first 24 hours of 
resuscitation for  sepsis -induced hypotension will reduce 90 -day in -hospi[INVESTIGATOR_34380].     
3.6 Endpoints  
3.6.1 Primary Outcome  
The primary outcome is all -cause mortality prior to discharge home before day 90.   “Home” is 
defined as a patient’s place of residence prior to enrollment.  Thus, if a patient is discharged to a 
location that is different from the place of residence prior to enrollment (e.g.  rehabilitation facility 
or hospi[INVESTIGATOR_6125]) then the patient will be followed until they return to their original location, [ADDRESS_335385].   
3.6.2 Secondary Outcomes  
1. 28-Day Organ Support Free Days  
Organ support free days is defined as a patient being alive and without assisted breathing, 
new renal replacement therapy, or vasopressors (beyond 48 hours).  Patients will be 
followed for use of organ support to death, hospi[INVESTIGATOR_274334] 27, whichever 
comes first.  Any day that a patient is alive and without organ support will represent days 
alive and free of organ support.  Since there will be a bias in the protocols to place patients on vasopressors in the restrictive group, vasopressor use prior to 48 hours will be excluded 
from this calculation for both groups.  
2. 28-day Ventilator Free Days (VFDs)  
VFDs depend on both duration of ventilation and mortality through study day 28. In 
participants who survive [ADDRESS_335386] study day of assisted breathing through day 28. For participants 
discharged with assisted ventilation (e.g., to LTAC facility) prior to day 28, a phone call will 
be required to assess ventilator and vital status at day 28. Participants discharged p rior to 
day 28 on unassisted breathing will be assumed to remain on unassisted breathing through 
day 28. Isolated periods of ventilation briefer than 24 hours for surgical procedures and 
ventilation solely for sleep disordered breathing do not count towards duration of ventilation. 
In participants who never require assisted breathing, duration of ventilation is zero. 
Participants who do not survive 28 days will be assigned zero VFD. VFD is undefined in 
participants with chronic/home mechanical ventilation (except solely for sleep disordered 
breathing) and they will be excluded from this analysis.  
3. 28-day Renal Replacement Therapy Free Days 
Renal replacement free days to day 28 are defined as the number of calendar days between randomization and 28 days later that the patient is alive and without new renal replacement 
therapy. We also follow the “last off” method.  Patients who died prior to day [ADDRESS_335387] 28 days are assigned zero renal replacement free days.  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        17 
 4. 28-day Vasopressor Free Days 
Vasopressor free days to day 28 are defined as the number of calendar days between day 2 
(eligib ility starting [ADDRESS_335388] randomization) and 26 days later that the patient is alive 
and without the use of vasopressor therapy. We also followed the “last off” method.  Patients 
who died prior to day [ADDRESS_335389] 2 8 
days are assigned zero vasopressor free days. 
5. 28-day ICU free days  
ICU free days to day 28 are defined as the number of days spent alive out of the ICU to day 
28.   
6. 28-day hospi[INVESTIGATOR_274335] 28 are defined as 28 days minus the number of days from 
randomization to discharge home.   If a patient has not been discharged home prior to study 
day 28 or dies prior to day 28, hospi[INVESTIGATOR_274336]. Patients transferred to another 
hospi[INVESTIGATOR_274337] 28 to assess this endpoint.  
7. Initiation of mechanical ventilation  to day 28  
Patients who receive invasive mechanical ventilation via endotracheal or tracheostomy tube, 
except those intubated solely for a procedure and extubated within 24 hours, through to 
study day 28 meet this endpoint.  Non- invasive mechanical ventilation will not be included 
as an outcome.  This is a binary outcome.  
8. Initiation of renal replacement  to day 28  
Patients who receive (new) renal replacement therapy through day 28 will meet this 
endpoint.  Patients with chronic renal replacement therapy initiated prior to the current sepsis illness will not be eligible to meet this endpoint.  
9. Change in creatinine -based KDIGO stage between baseline and 72 hours 
Renal function will be assessed using the KDIGO staging system (serum creatinine criteria 
only; not urine output) between baseline and 72 hours to assess for de novo acute kidney 
injury ( AKI) (e.g., meeting cri teria for AKI by [CONTACT_104746]) or worsening AKI (e.g., 
increasing severity). Due to the potential influence of treatment assignment on urine output, as well as the potential for inaccurate urine output data in patients without indwelling urinary catheter s, we will use only the KDIGO creatinine criteria. Patients on chronic renal 
replacement therapy will not be eligible for this endpoint determination.  
10. Change in SOFA score between baseline and [ADDRESS_335390] the closet previously known 
value.  If a patient is intubated or heavily sedated at either 0 or 72 hours, the GCS will be 
omitted when calculating the change in score.  If a patient was on renal replacement therapy prior to presentation, then the renal dysfunction component to the SOFA score will be 
omitted as well. (See Appendix C)  
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335391] with the patient or family members as well as a review of medical records  
and publicly available data sources.  We will use the national death index as a final check 
for patient with whom we are unable to confirm their vital status through other means . 
 
12. Development of ARDS within 7 days  
We will determine the presence and severity of ARDS for each day of mechanical ventilation 
to day 7 using the following approach:  for each ventilator day, if an ABG is available between 2:00 AM and 8:00 AM, measure P/F (PaO2, FiO2 and PEEP) for all ABGs during this time window daily to day 7. Or, for ventilator days that no ABG available between 2:00 
AM and 8:[ADDRESS_335392] imputed P/F from measured S/F (SpO2, FiO2, and 
PEEP).   
 For participants with P/F <300 or imputed P/F <300, FiO2 ≥40%, and PEEP ≥[ADDRESS_335393] CXR (or CT) performed on each ventilated day 
with valid P/F or imputed P/F <300 (to day 7). If no chest imaging studies are present that 
day, site investigators may review available imaging one day before or after to determine if 
ARDS imaging criteria met. ARDS imaging criteria are met if the images are consistent with ARDS (bilateral opacities not fully explained by [CONTACT_190371], lobar/lung collapse, or nodules). If 
equivocal, the reviewing investigator will adjudicate with additional investigators.  
13. Change in Circulating soluble IL -[ADDRESS_335394] blood specimens and measure circulating soluble IL -6 at enrollment, and then at 
24, and 72 hours.  
14. Supraventricular/ventricular tachycardia (SVT/VT) or new onset atrial 
fibrillation/flutter (AF)  to day 28  
The occurrence of one or more epi[INVESTIGATOR_1841] (sustained for more than 1 minute for SVT and AF, > 15 seconds for VT) during through day [ADDRESS_335395] receipt of vasopressors.  (patients on vasopressors prior to 
randomization excluded from this metric)  
We will u se a bedside flow -sheet as a data collection instrument to record fluid and vasopressor 
administration, with the indications for administration, during the 24- hour protocol period. This 
will detail the delivery of the study interventions and assess protocol compliance.  The data will be reported to the protocol oversight committee (and disseminated to the sites as protocol 
compliance metrics) as aggregate per -arm data in a blinded fashion (e.g. descriptive numbers 
only without an “n” or any indication of outcome or clinical status).  This will occur at the 100, 200, and 300 patient data completion marks as descri bed in the feasibility evaluation phase 
(Section 8). After the feasibility evaluation phase, we will perform a simplified  data collection of 
summary fluid and  vasopressor administration during the [ADDRESS_335396] 10 patients  for any new site, and then quarterly, to allow 
treatment protocol adherence monitoring.  Any site with deficient compliance and/or separation 
of treatment arms  after the initial 10 patients or during the quarterly reports may rec eive re-
education and/or be asked to cease enrollment. 
The DSMB will also receive these data to assess the separation of intravenous fluid and/or 
vasopressor administration between study arms.  The DSMB will review these data during the 
protocol feasibilit y phase, as well as during scheduled interim analyses as outlined in the 
statistical plan.  
3.6.4 Subgroups for secondary analysis  
1. Patients receiving chronic  dialysis  
2. Patients with history of chronic heart failure ( as documented in past medical history ) 
3. Patients with qualifying SBP < 90 mmHg versus 90- 100 mmHg  at randomization 
4. Patients age > 65 years  of age  
5. Patients with a clinically confirmed infection as a cause of hypotension at study 
enrollment (as assessed by [CONTACT_274400][INVESTIGATOR_059])  
6. Patients with pneumonia as the etiology of sepsis  
7. Stratification by [CONTACT_274401]  
8. Patients enrolled in the ED (vs. wards or ICU) 
9. Patient with a history of hypertension  (as documented in past medical history or by [CONTACT_274402])  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        20 
 4. Study Population and Enrollment  
4.1 Number/Source Screening  
The trial will accrue a maximum of 2,320 patients. Patients will be recruited from the EDs, ICUs 
and other acute care areas of the PETA L Network Clinical Centers. The overall strategy is to 
screen and approach patients/surrogates for consent and enrollment earl y. 
4.2 Inclusion Criteria  
1. Age ≥ 18 years  
2. A suspected or confirmed infection (broadly defined by [CONTACT_274403])  
3. Sepsis -induced hypotension defined as systolic blood pressure < 100 mmHg or MAP < 
[ADDRESS_335397] 1 liter of fluid 
(*Fluids inclusive of pre -hospi[INVESTIGATOR_274324]; blood pressure must be below any known or 
reported pre- morbid baseline).  
4.3 Exclusion Criteria  
1. More than 4 hours elapsed since meeting inclusion criteria 
2. More than 24 hours elapsed since presentation to the hospi[INVESTIGATOR_307]  
3. Patient already received more than 3 liters of intravenous fluid (includes prehospi[INVESTIGATOR_274338])  
4. Unable to obtain informed consent   
5. Pregnancy  
6. Hypotension suspected to be due to non- sepsis cause (e.g.  hemorrhagic shock)  
7. Blood pressure is at known or reported baseline level  
8. Severe Volume Depletion from an acute condition other than sepsis.  
In the judgment of the treating physician, the patient has an acute condition other than 
sepsis causing (or indicative) of *severe volume depletion; 
Examples include: Diabetic ketoacidosis, high volume vomiting or diarrhea, 
hyperosmolar hyperglycemic state, and non- exertional hyperthermia (heat stroke); 
severe is defined by [CONTACT_274404]  
9. Pulmonary edema or clinical signs of new fluid overload (e.g. bilateral crackles, new 
oxygen requirement, new peripheral edema, fluid overload on chest x -ray) 
10. Treating physician unwilling to give additional fluids as directed by [CONTACT_274389]
* 
11. Treating physician unwilling to use vasopressors as directed by [CONTACT_274390] *.  
12. Current or imminent decision to withhold most/all life- sustaining treatment; this does not  
exclude those patients committed to full support except cardiopulmonary resuscitation 
13. Immediate surgical intervention planned such that study procedures could not be followed   
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        21 
 14. Patient no longer meets the hypotension inclusion criterion (no available SBP < 100 or 
MAP < 65 within 30 minutes of randomization or not receiving a vasopressor infusion ) 
15. Prior enrollment in this study   
 
*Patients will be excluded i f the attending physicians believes that either study arm is not 
good clinical care for his/her patient in their clinical judgement (see Appendix I)   
 
4.[ADDRESS_335398] the study 
hypothesis of early resuscitation strategies.  Criterion 3 excludes patients who already exceed 
resuscitation volumes in excess of early goals the restrictive fluid group. Criteria 4 excludes 
patients where consent is unable to be obtained.  Exclusion criterion 5 is included because 
there are not sufficient data to support either of the two treatment arms during pregnancy. Non-
septic causes of shock (criterion 6) are excluded as the treatment differs from the study 
interventions.  Criterion 7 excludes patients with normally low blood pressure who are unlikely to 
benefit from the blood pressure targets of this study.  Criterion 8 excludes patients who are 
severely volume deplete who may require large volumes of intravenous fluids to treat non-
sepsis conditions such that compliance with a restrictive fluid approach i s not feasible.  Criterion 
9 excludes patients who may not tolerate the fluid goals of the liberal fluid group. Criterion 10 
excludes patients where physicians are unwilling to administer additional fluids and thus would 
not be able to comply with the study treatment protocol.  Criterion 11 excludes patients where 
physicians are unwilling to administer vasopressors and thus would not be able to comply with the study treatment protocol.  Criterion 12 excludes patients who may not survive to important 
study endpoints or whose underlying condition or ventilator management complicates assessment of the secondary endpoint of ventilator free days. Investigators will not be able to 
execute study procedures in the operating room (criterion 1 3).  Patients who have already been 
enrolled will not be allowed to participate twice (criterion 15 ).  
4.[ADDRESS_335399] be randomized within 4 hours of meeting inclusion criteria. The window for 
randomization begins at the time of meeting all inclusion criteria, regardless of patient location in 
the hospi[INVESTIGATOR_307].  
4.6 Screening Log  
All patients meeting inclusion criteria will be entered on a screening log. If the patient is not 
enrolled, the screening log will include information explaining why enrollment did not occur (e.g., 
exclusion criteria, attending physician denial, patient refusal) and baseline demographic 
information only will be collected.  
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335400]’s legal 
authorized representative (LAR), we will randomize subjects via the coordinating center web 
based randomization system. Each research coordinator will have a unique Personal 
Identification Number (PIN) to access the randomization system. Each subject will receive a 
computer -generated study ID number and study arm assignment to either the restrictive or 
liberal treatment arm. An emailed confirmation will be sent to the study site. Randomization will 
be stratified by [CONTACT_209847].  
4.8 Minorities and Women  
Access to women and racial minorities was considered by [CONTACT_274405]. The demographic profiles of the Centers selected for the Network show that 
the aggregate patient population contains representative proportions of minorities and women. Recruitment of minorities and women will be monitored by [CONTACT_274406]. If necessary, additional recruitment efforts will be made at specific centers to ensure 
that the aggregate patient sample contains appropriate gender and minority subsets.  
5. Study Procedures  
5.1 Restrictive Fluids Group (Early Vasopressors)  
Restrictive Group Treatment Protocol  
Once a patient is randomized to the restrictive fluids arm, the general approach will be to use 
vasopressors to treat hypotension as opposed to intravenous fluids.  Maintenance fluids should 
not be used.  Restoration of blood pressure and perfusion should be accomplished in 
accordance with the following protocol  recommendations : 
1. Initiate vasopressors (norepi[INVESTIGATOR_274339]-line vasopressor) for MAP < 65 
mmH g or SBP <90  mmHg  
2. Titrate vasopressors to:   65 mmHg < MAP <75 mmHg 
3. *“Rescue Fluids” are recommended, but not mandated, in 500 cc crystalloid boluses for any 
of the following:  
a. Severe hypotension (SBP <70 mmHg or MAP <50 mmH g)  
b. Refractory hypotension (MAP <65 mmHg) despi[INVESTIGATOR_274340] 20 
mcg/min or 0.25 mcg/kg/min or equivalent dose of another vasopressor  (see 
Appendix E)  
c. Lactate > 4 mmol/L and rising from previous lactate, after at least 2 hours of therapy , 
in patients with serial lactates measured in usual care practice  
d. Sinus heart rate > 130 beats per minute for >15 minutes  
e. Evidence of extreme volume depletion from hemodynamic monitoring (if performed) based on any of the following:  
i. Maximal IVC diameter < 5mm; or  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        23 
 ii. Empty left ventricle on echo ( i.e. left-ventricular end- diastolic area index < 5.5 
cm2/m2 BSA) or  
iii. Substantial volume responsiveness defined as stroke volume increase > 30% in 
response to a passive leg raise, fluid challenge, or positive pressure breaths 
during passive ventilation)  
 
*Rescue fluids may be administered  at any time if the  clinical team believes that it is in the 
best interest of the patient  
 
4. Patients should be monitored for volume overload, and fluids may be halted or reduced for 
clinical evidence of *symptomatic left atrial hypertension based on a clinical diagnosis  by [CONTACT_274407].  
a. *Clinical features of symptomatic LA hypertension:  
signs and symptoms of fluid overload (or  hydrostatic edema due to  left atrial 
hypertension) include manifestations such as  increased respi[INVESTIGATOR_697], increased 
use of accessory muscles of respi[INVESTIGATOR_1516], increased bilateral inspi[INVESTIGATOR_274341], increasing oxygen requirement, or pulmonary edema on chest x -ray likelycardiogenic 
in origin).  
5. Return to care without study guidance for any of the following protocol endpoints: 
a. Suspi[INVESTIGATOR_274342] (e.g. bowel) or peripheral (e.g. limb or digit) ischemia or presence of mottling 
b. > [ADDRESS_335401] elapsed since protocol initiation  
If fluids are used, a balanced crystalloid solution (such as lactated Ringers , Hartman’s 
solution, Plasmalyte or Normosol)  is recommended, normal saline is permitted.  If a p atien t 
received less than [ADDRESS_335402] of the patient.  
. 
5.2 Liberal Fluids Group  
Liberal Empi[INVESTIGATOR_274343]  
1. Initiate a 2000  cc crystalloid fluid infusion upon randomization ( 2000 cc to be complete 
within 180 minutes of randomization; clinician may extend infusion time at any point during the 2000 cc infusion if indicated for a given patient ); monitor for signs of fluid overload  
2. Clinical evaluation at the end of first 1000cc : 
- If blood pressure  and
 heart rate have normalized ( SBP ≥ 110 mmHg or MAP ≥ 70 
mmH g and HR < 90  bpm) and clinical assessment is patient is volume replete, team 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        24 
 may forego second liter and move to 500cc boluses based on fluid triggers (#5 
below) ; otherwise continue with second 1000cc infusion  
3. Maintenance fluids should not be used . 
4. Balanced crystalloid solution (such as lactated Ringers, Hartman’s solution, Plasmalyte 
or Normosol)  is recommended, normal saline is permitted.   
5. Subjects receive a 500cc crystalloid fluid bolus for any of the following fluid triggers:  
a. SBP < 90 mmH g or MA P <65  mmH g 
b. Lactate > 4 mmol/l  and rising in patients with serial lactates measured as part of 
usual  care practices  
c. R educed urine output (<30 cc/hour) for > 1 hour (except for ESRD patients) 
d. Sinus heart rate > 110 beats per minute  
e. Any measured/clinical assessment of volume status or volume responsiveness (e.g. 
echo, IVC measurement, CVP, etc) suggesting benefit from additional fluid (as defined by [CONTACT_274408])  
f. Receiving vasopressors to maintain SBP ≥ 90 mmHg or MAP ≥ 65 mmHg  
6. Patients should be monitored for volume overload, and fluids may be halted or reduced for clinical evidence of *symptomatic left atrial hypertension based on a clinical diagnosis  by [CONTACT_274409].  
a. *Clinical features of symptomatic LA  hypertension:  
signs and symptoms of fluid overload (or  hydrostatic edema due to  left atrial 
hypertension) include manifestations such as  increased respi[INVESTIGATOR_697], 
increased use of accessory muscles of respi[INVESTIGATOR_1516], increased bilateral inspi[INVESTIGATOR_274344], increasing oxygen requirement, or pulmonary edema on chest x -ray 
likely cardiogenic in origin).  
7.  “Rescue vasopressors”  recommended  (in the form of norepi[INVESTIGATOR_271882]) for any of 
the following criteria:  
a. SBP < 70 mmHg or MAP < [ADDRESS_335403] 5  minutes)  
b. Signs of volume  overload  (see above)  with persistent hypotension/hypoperfusion  
c. Lactate > 4 mmol/L and rising from previous lactate, after at least 2 hours of therapy  
d. SBP < 90 mmHg after administration of 5000 cc of volume (includes all pre-
randomization and post -randomization fluids or blood products) -   transition to all 
decisions made by [CONTACT_274410]  
*Vasopressors may be administered at any time if the clinical team believes that it is in the best 
interest of the patient, and then weaned off safely once the fluid boluses have their effect. 
 
8. . Return to care without study guidance for any of the following:  
a. ≥ 5 liters of total IV fluids  administered  (including both pre-randomization and 
post-randomization intravenous fluids)  
b. > [ADDRESS_335404] elapsed since protocol initiation  
c. Suspi[INVESTIGATOR_274342] (e.g. bowel) or peripheral (e.g. limb or digit) ischemia or 
presence of mottling 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        25 
 5.3 The Use of Cardiac Ultrasound and Other Hemodynamic Monitoring 
Techniques  
The use of advanced monitoring techniques, such as echocardiography , pulse contour analysis, 
bioimpedence and bioreactance, will be permitted but not mandated.  If the clinician wishes to 
use these techniques, fluid administration should be titrated according to the CLOVERS study 
fluid protocol guidelines.  In the restrictive group, clinical teams should refrain from adjusting 
treatment intervention outside the guidance provided whereby [CONTACT_274411] “Rescue Fluid” indications stated in the protocol (Section 5.1.c) unless the clinical 
team believes that alternative approaches would be in the best interest of the patient .  In the fluid  
liberal group, we permit the clinician to use these techniques and allow for fluid boluses based 
on any provider -chosen metric of volume responsiveness.   
6. Duration of the Protocol  
The protocols are intended to run for [ADDRESS_335405] randomization. Fluid management after 24 
hours will be dictated solely by [CONTACT_6098].  
6.1 Common Strategies for Both Study Groups  
6.1.1  Permitted Fluid Types  
Balanced crystalloid solution (such as lactated Ringers, Hartman’s solution, Plasmalyte or 
Normosol)  is preferred, any  isotonic crystalloid  is permitted.  We  recognize that there is 
theoretical rationale for using a balanced solution approach; however, given the lack of clear evidence identifying a superior approach, the type of fluid administered will be tracked but not 
mandated.   
6.1.[ADDRESS_335406] practice strategies.   
Weaning :  Since the time a patient achieves unassisted ventilation affects some secondary 
endpoints, and because recent evidence- based consensus recommendations have identified a 
best practice for weaning, a weaning strategy will be controlled by [CONTACT_274412]- based recommendations. This will assure similar weaning methods and 
provide potential benefit to both study groups.  This weaning strategy is a simplified version of the protocolized weaning strategy used in prior ARDS Network studies (Appendix D). 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        26 
 6.1.4  Vasopressor Use  
Vasopressor dosing should be titrated to achieve a 65mmHg < MAP < 75 mmHg. Vasopres sor 
administration is permitted through either a central line or a 20 gauge or larger peripheral IV 
catheter.  
Vasopressor Weaning : Since the time a patient achieves independence from vasopressors 
affects some secondary endpoints, we will use a slightly modified version of the vasopressor 
weaning protocol previously used in ARDSNet (Appendix E).  This protocol will be distributed to 
the clinical team who will implement the protocol.  
6.1.5  Fluid management After Protocol Conclusion (post 24 hours)  
For both treatmen t arms, each site will revert to care without study guidance fluid for 
management practices [ADDRESS_335407] to the 
time of randomization will be recorded. If no values are available from the 24 hours prior to randomization, then values will be measured up to 24 hours. All values will be derived from 
clinically available data.  (see Time of Events Schedule in Appendix F)  
1. Demographic and Admission Data (including age, sex, race)  
2. Pertinent Medical History and Physical Examination (including components of the 
Charlson co- morbidity score)  
3. Height; gender; measured Body Weight (mBW); calculated predicted body weight (PBW); body mass index (BMI)  
4. Location when inclusion criteria met: ED, ward, ICU, referring hospi[INVESTIGATOR_307]  
5. Vital signs:  heart rate (beats / min), systemic systolic and diastolic BP (mmHg), body 
temperature (
0C), and oxygen saturation with Fi O2 
6. Clinical laboratory testing results  
7. Presumed site of infection 
8. SOFA Score: as described in Appendix C  
9. Attending physician assessment of CLOVERS eligibility (Appendix I)  
7.2 Assessments during  Protocol Phase  
1. Type, timing, and volume of fluid administration 
2. Type, timing, and dosing of vasopressor administration  
3. Fluid  inputs and outputs as clinically recorded  
4. Identification of clinical signs and symptoms of fluid overload  
5. Oxygen delivered by [CONTACT_274413] (including nasal high flow oxygen), 
non-invasive ventilation by [CONTACT_274414], and intubation 
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335408] 7 days  
5. Daily fluid outputs (truncated for death or ICU discharge) for the first [ADDRESS_335409] 72 hours after 
randomization 
9. SOFA at hours 0 and 72  
7.4 Specimen C ollection  
Plasma  will be collected within 2 hours of randomization, at 24 hours, and at 72 hours, frozen, 
and stored at a biorepository for future research. When consent for genetic testing is specifically 
obtained, an additional 20 ml of whole blood for future RNA and DNA studies will also be 
collected.  Total blood volume for these draws is approximately 30 ml/day, for a total of 
approximately [ADDRESS_335410] the causative etiology of the hypotension: 
We will perform  an assessment using all testing and records available during the 
hospi[INVESTIGATOR_274345] a site investigator will make an assessment as to whether the 
hypotension at enrollment was likely due to an infection or not.  
8. Feasibility Evaluation Plan  
The protocol oversight committee, steering committee, and the DSMB will monitor the trial for 
feasibility during the initial phase of the trial ( ~300 patients will be assessed during 3 separate 
looks).  After ~[ADDRESS_335411] 100 additional patients are enrolled after any protocol 
modification (i.e., subjects 200 and 300 if no modifications; however, if as an example 30 patients were enrolled after an assessment at 100 patients but before the amended protocol 
was active, then the next assessment would occur after 230 patients were enrolled).  To minimize time during this assessment phase, key data points such as fluid and vasopressor 
administration will be identified and completion for key elements will be required within [ADDRESS_335412] on the  planned interim analyses and the final efficacy analysis.  
 
Feasibility parameters (by [CONTACT_15500]) will include:  
1. Subject accrual  
2. Compliance with treatment protocols  
3. Separation of the groups based on fluid and vasopressor administration data  
The protocol committee, steering committee, and DSMB will have available demographic data, 
criteria for separation, study accrual, and compliance.  The DSMB (only) will have available 
adverse event data.   
 At that point, the protocol committee will issue one of three recommendations  to the steering 
committee for decision:  
 a) Continue without protocol modification,  
b) Continue with protocol modification c) Halt  the trial .   
 The steering committee will  be asked to approve  the recommendation.  Once the protocol 
committee and steering committee are in agreement, the responses will be provided to the 
DSMB, who will be charged with assessing whether there are any safety  concerns. The DSMB 
will then have the opportunity to approve the recommendation or make additional recommendations.  At the completion of the feasibility evaluation phase, if the study continues, 
all patients from the feasibility evaluation phase will be retained in the ITT analysis. No outcome data will be released in any form.  
 During the feasibility evaluation phase, the DSMB will also review:  
1. Adverse Events  
2. Central line use and any associated complications  
8.[ADDRESS_335413] Accrual  
The maximum sample size for the study is 2,320 subjects.  We estimate that sample size is 
achievable in a timely fashion if we enroll an average of 1 patient/site/month, distributed across 
50 enrolling sites.   For the feasibility assessment phase, if the enrolling sites achieve > 70% of 
this rate (> 0. 7 patients/site/month), then the feasibility guideline for patient accrual will have 
been met.  A site will be defined as “started” when the site indicates that they have begun 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        29 
 screening, and the #patients/month/sites will be calculated as the number of patients enrolled 
across all sites, divided by [CONTACT_274415], and number of sites.  A calendar month is defined by [CONTACT_274416], 
divided by 30.  If a site withdraws from the study, then they will stop contributing patients and 
calendar months.  
8.[ADDRESS_335414] 24 
hours by [CONTACT_185118] a detailed flow sheet.  We will assess protocol compliance (defined as 
following the protocol rules based on vital signs and actions) for the first [ADDRESS_335415] actions among the total actions perfor med; or (correct actions)/(correct +incorrect actions) X100.   
 
A “correct action” in the liberal group is defined as:  
a. Administration of the initial 2-liter fluid infusion within the first 180 minutes  (if documented 
clinical assessment leads to a decision to administer less than two liters during the initial infusion or if the infusion time is deliberately lengthened, this is considered a correct action) 
b. Administration of a minimum 500cc fluid bolus when a “meets intervention criteri on” is 
present  
c. V asopressor use in the presence of a “rescue criteri on”  
d. No fluid or vasopressor administration in the absence of a meets intervention criteri on 
 
An “incorrect action” in the liberal group is defined as:  
a. Failure to administer the initial 2-liter fluid infusion  within the first 180 minutes (if clinical 
evaluation is that patient has normalized  - fluids may stop and be considered a correct 
action).  
b. Failure to administer a 500cc fluid bolus when a “meets intervention criteri on” is present and 
there  is no contraindication (e.g. fluid overload or > 5 liter s criteria already administered ) 
c. U se of a vasopressor in the absence of a “rescue vasopressors recommended” criteri on 
NOTE: In both arms, fluids or  vasopressors can be used at any time if the clinical team feels 
they are in the best interest of the patient.  An incorrect  action as defined in the protocol is 
not a protocol deviation but would be considered non- compliant for the purposes of 
compliance monitoring.  
A “correct action” in the restrictive group is defined as:  
a. Initiation of vasopressors for SBP < 90mmHg  and/or MAP <65mmHg  within 60 minutes  
b. Titration of vasopressors to maintain MAP ≥ 65mmHg 
c. A dministration of a 500cc fluid bolus in the presence of a “rescue fluid” criteri on  
d. Administration of fluid boluses to up to 2 liters of total fluid, including pre- randomization fluid, 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        30 
 at the discretion of the clinical team even where “rescue fluid” criteria are not met . 
e. No fluid or vasopressor administration/titration in the absence of a meets intervention 
criteri on 
An “incorrect action” in the restrictive group is defined as:  
a. Failure to initiate vasopressors for  SBP < 90mmHg and/or MAP <65mmHg within 60 
minutes  
b. Failure to titrate vasopressors for sustained (greater than 30 minutes) MAP < 65 mmHg   
c. A dministration of intravenous fluid in the absence a “rescue  fluids recommended” criteria  
d. NOTE : In both arms, fluids or  vasopressors can be used at any time if the clinical team feels 
they are in the best interest of the patient .  An incorrect action is not  a protocol deviation but 
would be considered non -compliant for the purposes of compliance monitoring.  
 
The goal is to achieve > 70% compliance with instructions across  enrolling sites.   Summative 
data will be shared with the protocol committee, steering committee, and the DSMB.   During this 
period, the protocol rules may be refined through iterative application and evaluation in the 
enrolling sites.   If compliance is lower than 70%, but the separation of intravenous fluid volumes 
and/or vasopressor use between groups is met, amendments may be considered to try to improve compliance, but the trial will be considered feasible and will continue.  
To maintain blinding to outcomes, the reports will be aggregated without reference to patient number.  They will not include any information beyond the 24- hour treatment protocol period.  
The protocol oversight committee, PETAL steering committee and/or the DSMB may ask that detailed iterative refinement continue at each [ADDRESS_335416] 300 enrolled patients, with staged evaluations at 100, 200, 
and 300 patients to allow modification of experimental protocols to improve compliance and/or 
experimental separation. The trial can be stopped at 100, 200, or 300 patients based on the 
below criteria if there is evidence of lack of feasibility by [CONTACT_274417], protocol compliance, 
and/or anticipated separation.     
A decision to move to the next phase of the trial will be based on the likelihood of meeting 2 of 
the following 3 separation guidelines at the end of the trial:  
1. Difference of 1000cc (or greater) fluid administered over the first 6 hours of the 
treatment protocol  
2. Difference of 1000cc (or greater) fluid administered over the first 24 hours of the 
treatment protocol  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        31 
 3. Differe nce of 3 hours (or greater) of mean time of vasopressor use over the first [ADDRESS_335417] the 
opportunity to modify the protocol to optimize recruitment, protocol compliance, and treatment 
group separation. Fluid separation at 6 and 24  hours  will be analyzed as follows:  we will 
regress the log of the fluids administered on the treatment group and report the difference in the exponentiated means between the treatment groups and the confidence interval of this difference. This estimate is equivalent to the difference in the medians under the log- normal 
distribution, but the confidence limits are narrower due to the use of a parametric model. If the fit 
to the log- normal distribution is poor,  we will estimate the difference in medians using quantile 
regression.  If changes to significantly improve  separation are not likely,  and the upper end of a 
90% confidence interval on the difference in medians is less than 1 liter, we will consider 
recommending that the study be stopped.  (Note: This is equivalent to a test of the hypothesis 
HO that the true difference is [ADDRESS_335418] the one-sided alternative that the true difference is 
less than one liter, with a one- sided p -value of 0.1).  
During these looks, we will exclude data from patients managed by a no- longer -current protocol 
(i.e., in the event that a protocol change was implemented at the  100 or 200- patient marks). The 
goal is to preserve 90% power to detect a true separation between treatment arms in the overall 
trial of 1000ml at [ADDRESS_335419] a 90% probability of stoppi[INVESTIGATOR_274346] 0.[ADDRESS_335420] 2 of 3 feasibility guideline parameters for separation are met, the separation 
parameter guideline is met.   If none of the guideline parameters are met, the protocol oversight 
committee will recommend termination of the trial. If one of the parameters is met, then the 
protocol oversight committee will examine the data to determine whether there is adequate 
separation or if a protocol modification is likely to lead to increased separation.   At each of the 
feasibility assessment evaluations, the protocol oversight committee will determine whether 
separation guidelines  are adequately fulfilled and make a recommendation to the SC, and 
DSMB.  The DSMB has final decision- making authority.    
8.4 Assessment of Eligibility Criteria  
We will assess the subset of patients enrolled with a qualifying blood pressure of 90 ≤ SBP < 
[ADDRESS_335421] of the trial.  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        32 
 9. Statistical Considerations  
9.1   Sample Size and Stoppi[INVESTIGATOR_274347]- to-treat 90-day all cause in- hospi[INVESTIGATOR_34380], where in-
hospi[INVESTIGATOR_274348] (i.e. transfer hospi[INVESTIGATOR_274349]). Subjects 
who are discharged home (defined as residence prior to admission) prior to day 90 will be assumed to be alive at day 90.  
Sample size is based on a comparison of binomial proportions with an overall two- sided alpha 
level of 0.05 and power of 0.90.  With 15% mortality rate in liberal fluid group and 10.5% 
mortality rate in the restrictive group, maximum required total sample size is 2320 subjects.  
The presumed 15% mortality rate in the liberal fluid group is based on several recently published clinical trials (Process [2], ARISE [3], Promise [4] ). 
This trial will stop for efficacy of either the restrictive or liberal fluid strategy arm, or futility. The 
study is designed with a symmetric group sequential t^4 alpha error spending function and a 
symmetric non- binding t^[ADDRESS_335422] two interim analyses and one final analysis that will be approximately evenly 
spaced.  However, the scheduling of the DSMB meetings may alter this schedule.    
Tables 1 and 2 present the stoppi[INVESTIGATOR_274350]. The tables present stoppi[INVESTIGATOR_274351] a one -sided p- value or an 
observed mortality difference.   Table 3 present s the probability of stoppi[INVESTIGATOR_274352] (no effect of fluid) and alternative (restrictive fluid reduces mortality from 15% to 10.5%) 
hypotheses respectively.  
 
Table 1. Stoppi[INVESTIGATOR_274353]: One Sided P Values  
Stage  Sample Size  Lower Efficacy  Lower Futility  Upper Futility  Upper Efficacy  
1 773 0.0003086  . . 0.[ZIP_CODE]  
2 1547  0.[ZIP_CODE]  0.[ZIP_CODE]  0.[ZIP_CODE]  0.[ZIP_CODE]  
3 2320  0.[ZIP_CODE]  0.[ZIP_CODE]  0.[ZIP_CODE]  0.[ZIP_CODE]  
 
  
 Table 2. Stoppi[INVESTIGATOR_274353]: Mortality Differences 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        33 
 Stage  Sample Size  Lower Efficacy  Lower Futility  Upper Futility  Upper Efficacy  
1 773 -0.[ZIP_CODE]  . . 0.[ZIP_CODE]  
2 1547  -0.[ZIP_CODE]  -0.[ZIP_CODE]  0.[ZIP_CODE]  0.[ZIP_CODE]  
3 2320  -0.[ZIP_CODE]  -0.[ZIP_CODE]  0.[ZIP_CODE]  0.[ZIP_CODE]  
 
  Table 3. Cumulative Stoppi[INVESTIGATOR_274354]: Reject Null  
Given Null  Stop: Accept Null  
Given Null  Stop: Reject Null  
Given Alternative  Stop: Accept Null  
Given Alternative  
[ADDRESS_335423] is that the absolute difference in mortality rates was 4.5% and the second 
was a 30% relative difference.  The second row of the table shows the current assumptions.  
Whether the absolute or the relative difference is used, the power remains above 85%. 
Table 4. Sensitivity to Assumed Null Mortality  
   
 
 Null Mortality  Power at 4.5% Absolute 
Decrease in Mortality  Power at 30% Relative 
Decrease in Mortality  
17% 0.86 0.93 
15% *  0.90 0.90 
13% 0.94 0.85 
*Assumption used in the CLOVERS Protocol  
 
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335424] meaningful differences in important 
secondary outcomes.  For example, we believe that organ failure free days to day 28 (e.g. not 
intubated, nor receiving renal replacement therapy, and not on vasopressors after a 48-hour 
period of protocol washout) is a relevant and meaningful outcome.  In fact, since this is a study 
where one must select an approach that will resemble one of the strategies (e.g. this is a test o f 
existing therapi[INVESTIGATOR_014], not of a novel therapy that would require adoption) a meaningful difference in 
organ failure free days would be a meaningful study result that would alter treatment practices.  
To demonstrate the power for organ failure free days – we use published data from the 
PROMISE trial (which reported organ failure free days). PROMISE reported organ failure free 
days to day 28  in usual care (mean +/ - standard deviation) for cardiovascular (20.6 +/ - 11.9), 
respi[INVESTIGATOR_696]  (19.8  +/- 12.0), and renal (20.6 +/ - 11.9).  We assume that organ failure free days 
(combining all three organ systems) would be largely determined by [CONTACT_274418].  Since these components are all quite similar, we use a standard deviation of 12 
organ failure free days  for sample size calculations.  Consistent with the FACTT trial, we identify 
3 organ failure free days as clinically significant.  Using a two -side alpha of 0.05 we obtain 90% 
power to detect a true mean difference as outlined in the table below: 
Difference in Organ 
Failure Free Days  Total Patients  
[ADDRESS_335425] of Change in Fluid Protocol on Outcome  
The initial two -liter fluid infusion in the liberal fluid treatment group was modified to a one -liter 
fluid infusion  followed by [CONTACT_274419]’s discretion.  To 
understand the potential impact of this change in the liberal fluid treatment strategy on the 
primary outcome we will do an interaction analysis which will be presented as  shown in the 
following table.  
Table 5: All -Cause Mortality  Prior  to Discharge Home  Before Day 90  
Stratified  by [CONTACT_274420] (95% CI)  P-value 
Two-Liter Fluid Infusion Epoch 0.xxx±0.xxx  0.xxx±0.xxx  0.xxx (0.xxx, 0.xxx)  0.xxx 
One-Liter Fluid Infusion Epoch  0.xxx±0.xxx  0.xxx±0.xxx  0.xxx (0.xxx, 0.xxx)  0.xxx 
Interaction    0.xxx (0.xxx, 0.xxx)  0.xxx 
 
 
 
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335426] comparison of all participants 
randomized to liberal fluid and all those randomized to restrictive fluid unstratified by [CONTACT_274421].  
Table 6: All -Cause Mortality  Prior  to Discharge Home  Before Day 90  
 
Liberal Fluid Group  Restrictive Fluid Group  Difference (95% CI)  P-value 
0.xxx±0.xxx  0.xxx±0.xxx  0.xxx (0.xxx, 0.xxx)  0.xxx 
Interactions between the liberal and restrictive treatment groups and the two liberal fluid 
treatment epochs for study process metrics, such as intervention period fluid and vasopressor 
use, and selected secondary outcomes may also be reported as in Table 5 above.  
10. Data Collection and Monitoring  
Data Collection: The research coordinators will transfer data to the Clinical Coordinating 
Center on a prescribed basis through a secure web- based data collection program.  
Investigators will use these reports to identify aspects of protocol management that can be 
improved at their Centers. The on- target performances of all centers will also be included, 
allowing investigators at each center to know how their center is performing relative to other PETAL Centers. On-t arget performances will be discussed during regular meetings of the 
Steering Committee. The Institutional Support Committee will provide advice and assistance to Centers that are not performing up to expectations. On- target data for the specific variables 
according to study group will be included in the primary reports of the results of the individual trials.  
Site Monitoring: Data quality will be reviewed remotely using front end range and logic checks 
at the time of data entry and back -end monitoring of data using SAS reports. Additionally, 
Clinical Center on site visits will be performed on a regular basis by [CONTACT_274422]. 
Patient records and case report forms will be examined on a spot check basis to evaluate the 
accuracy of the data entered into the database and monitor for protocol compliance.  
11. Risk Assessment  
This study involves randomization to early restrictive fluids and early vasopressors versus l iberal 
fluids with rescue vasopressor use for the first 24 hours.  
11.1 Potential Risks to Subjects  
Risk of Fluid Administration : Patients in the liberal fluid protocol may receive additional 
intravenous fluids.  This carries the potential risk of fluid overload, including acute congestive 
heart failure, breathing difficulties, and increased peripheral edema.  
 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        36 
 Risk of Vasopressor Administration: Patients in the restrictive protocol may receive early or 
additional vasopressors based on the treatment assignment. The potential risks of early 
vasopressors include cardiac ischemia, cardiac dysrhythmias, bowel ischemia, or limb ischemia.  
 Risks of Blood Draws : 
All patients will have blood drawn for research purposes. Many patients 
will have invasive lines placed for clinical purposes, where the risk of blood draws are extremely 
low, as blood can usually be easily obtained from these lines. In cases where an invasive line is 
not present, the risks of drawing blood are uncommon and include bleeding and bruising. 
Commonly, drawing blood is painful, and rarely, drawing blood can lead to infections at the site of the blood draw.  
 
Risk of Line Placement: Patie nts with hypotension will often have central venous access placed 
to increase venous access in the anticipation of the need for reliable and increased access for 
fluid, medication, and vasopressor administration.   However, if restoration of blood pressure 
occurs without needing vasopressor medications, clinicians may decide to not place central 
venous access.   Additionally, clinicians may opt to use peripheral venous access to administer 
vasopressors. The restrictive fluids protocol is intended to facilitate an increase in the utilization 
of vasopressors; thus, this practice may lead to an increase in the placement of central venous 
catheters.   The decision to place a central venous line will be left to the treating and/or study 
clinician.   It is possible th at additional central venous catheters will be placed in the fluid 
restrictive group.   The risks of central venous access include infection, pneumothorax 
(punctured lung), and vessel injury, inclusive of inadvertent arterial cannulation.  
Peripheral Vasopressor Utilization : Peripheral vasopressor administration is permitted in this 
protocol .  The risk of peripheral vasopressors utilization is extravasation and soft -tissue 
toxicity/injury  if extravasation occurs . 
11.2 Risk of Death  
It is possible that one treatment arm may lead to more deaths; mortality will be monitored during 
the course of the study.  
11.3 Minimization of Risk 
Federal regulations at 45 CFR 46.111(a)(1) require that risks to subjects are minimized by [CONTACT_191693]. There are several elements of study design inherent in the present protocol that meets this human subject protection requirement. The DSMB will be reviewing data as outlined above and will examine not only 
efficacy but safety (inclusive of mortality) and will reserve the right to halt the study at any time.  
11.[ADDRESS_335427] ive or liberal arm shown to be superior, then patients in that arm may receive benefit.  
However, the optimal strategy is undefined at this point.  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        37 
 11.5 Risks in Relation to Anticipated Be nefits  
Federal regulations at 45 CFR 46.111 (a)(2) require that “the risks to subjects are reasonable in 
relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that 
may reasonably be expected to result.”  Based on the preceding assessment of risks and 
potential benefits, the risks to subjects are reasonable in relation to anticipated benefits.   
12. Human Subjects  
Each study participant or a LAR must sign and date an informed consent form. Institutional review board approval will be required before any subject is entered into the study. PETAL will 
use a central IRB.  
12.1.  Selection of Subjects  
Federal regulations at 45 CFR 46(a)(3) require the equitable selection of subjects. The EDs, 
ICUs, and other acute care areas of PETAL sites will be screened to determine if any patient 
meets inclusion and exclusion criteria. Data that have been collected as part of the routine 
management of the subject will be reviewed to determine eligibility. No protocol -specific tests or 
procedures will be performed as part of the screening process. If any subjects meet criteria for study enrollment, then the attending physician will be asked for permission to approach the 
patient or his/her LAR for informed consent. Study exclusion criteria neither unjustly exclude 
classes of individuals from participation in the research nor unjustly include classes of 
individuals from  participation in the research. Hence, the recruitment of subjects conforms to the 
principle of distributive justice.  
12.2.  Justification for Including Vulnerable Subjects  
The present research aims to investigate the safety and efficacy of a type of treatment f or 
patients with sepsis induced hypotension.  Due to the nature of sepsis induced hypotension, the 
vast majority of these patients will have impaired decision- making capabilities. This study 
cannot be conducted if limited to enrolling only those subjects w ith retained decision- making 
capacity. Hence, subjects recruited for this trial are not being unfairly burdened with involvement 
in this research simply because they are easily available.  
12.3.  Informed Consent  
Federal regulations 45 CFR 46.111(a)(5) require that informed consent will be sought from 
each prospective subject or the subject’s LAR. The one obtaining consent is responsible for 
ensuring that the patient and/or LAR understands the risks and benefits of participating in the 
study, and answering any questions the LAR may have throughout the study and sharing any new information in a timely manner that may be relevant to the LAR’s willingness to permit the subject’s continued participation in the trial. The consenter will make every effort to minimize coercion. All study participants or their LARs will be informed of the objectives of the study and 
the potential risks. The informed consent document will be used to explain the risks and benefits of study participation to the LAR in simple terms before the patient is entered into the study, and to document that the LAR is satisfied with his or her understanding of the risks and 
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335428] been ruled out for COVID -19 at the time of consent, the use of “no -touch” consent 
methods will  be allowed.  Additionally, the electronic consent platform facilitates documentation 
of informed consent from legal authorized representatives who are not present in the hospi[INVESTIGATOR_274355].  
Below, we outli ne three examples of no -touch consent procedures that may be used: (a) a 
paper -based approach  (method 1) ; (b) a second paper -based approach (method 2); and (c) an 
electronic/e -consent approach  
a)  Paper -based approach  method 1  
1. The informed consent document is  delivered to the patient or LAR.  
a. If the patient or LAR is on- site, the informed consent document many be delivered to 
the patient or LAR either by [CONTACT_274423]  
b. If the LAR is off -site, the informed consent document may be emailed, faxed, or 
otherwise electronically transferred to the LAR (method dictated by [CONTACT_274424])  
2. Research staff discuss the informed consent document with the patient or LAR either in-person or by [CONTACT_191648].  This step confirms subject/LAR i dentity . 
3. If the patient or LAR decides to consent to participate, the patient or LAR signs and dates the paper copy of the informed consent document.  
4. A photograph is taken of the signature [CONTACT_274457] (e.g. REDCap).  
a. If using the patient’s device (such as a patient’s personal cellular phone), a survey 
link can be sent to their device to allow direct upload of the image into the electronic 
database (e.g. REDCap).  
b. If using a staff device, it must be approved to store PHI by [CONTACT_7848]. In that case, research personnel can take a photograph of the signature [CONTACT_274458]’s room.  The photograph can then be uploaded into the electronic database.  If a staff device is taken into the patient’s room to take a photograph it must be able to be disinfected according to local institutional practices.  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        39 
 5. Research staff (and witness  if applicable based on local requirements)  provide signatures 
within the electronic database (e.g. REDCap) confirming their participation in the informed 
consent process.  
6. The patient or LAR retains the paper consent document. The image of the signature [CONTACT_191706] a copy of the blank informed consent document for research records.  
b) Paper -based approach  method 2  
A photograph of the signed ICF can be transmitted to trial staff.  
1. An unsigned ICF is provided to the patient by a person who has entered the room.  
2. The investigator/designee arranges a telephone call or videoconference call with the patient 
(and, if desired and feasible, additional individuals requested by [CONTACT_102] [e.g., next of 
kin]).  
3. To ensure the patients are approached in a consistent fashion, a standard process should be used that will accomplish the following:  
a) Identification of who is on the call.  
b) Review of the ICF with the patient by [CONTACT_093]/designee and response to any 
questions the patient may have. 
c) Verbal confirmation by [CONTACT_274425], that they 
would like to participate in the trial, and that they have signed and dated the ICF that is in their possession.  
4. The patient  (or an individual in the room) takes a photograph of the signed and dated ICF 
and sends it to the investigator/designee.  
5. Research staff and LAR/patient provide signatures confirming their participation in the 
informed consent process.  
6. The patient or LAR retains the paper consent document. The image of the signature [CONTACT_274459] a copy of the blank informed consent documents for 
research records.    
c)  Electronic/e -consent approach  
1. The electronic informed consent document is opened on a research device or a link for the 
electronic informed consent  document is sent to the patient’s or LAR’s device.  
2. Research staff discuss the informed consent document with the patient or LAR either in person or by [CONTACT_191648].  This step confirms subject/LAR identity . 
3. If the patient or LAR decides to consent to participate the patient or LAR signs the electronic 
informed consent document.  This signature [CONTACT_191704]:  
a. an actual signature (often tracing a finger on the screen) OR  
b. a username [CONTACT_191705] 
4. Research staff  and witness (if required by [CONTACT_141798]) provide signatures within 
the electronic database (e.g., REDCap) confirming their participation in the informed consent process.  
 
 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        40 
 If a hospi[INVESTIGATOR_191569] -based consent, that device will be 
disinfected according to institutional protocols and removed by [CONTACT_274426]’s room.  
This approach complies with relevant regulations and sub-regulator guidance at 45 CFR 46.117, 
45 CFR 164.512, 21 CFR 11 Subpart C (11.100– 11.300), https://www.hhs.gov/ohrp/regulations -
and-p olicy/guidance/use -electronic -informed -consent -questions -and-answers/index.html , 
https://www.fda.gov/regulatory -information/search -fda-guidance- documents/informed- consent  
The information for the informed consent discussion will be provided in a formal document (or electronic equivalent) that has been approved by [CONTACT_274427] a language comprehensible to 
the potential participant, using an interpreter if necessary. The information presented in the 
consent form and by [CONTACT_274428], including any potential risks or benefits of taking part. It will be clearly stated that the participant is free to withdraw from the trial at any time for any reason without prejudice to 
future care, and with no obligation to give the reason for withdrawal. Where a patient does not 
speak English, a short -form consent and qualified interpreter will be employed, using similar 
“no-touch” principles.  Use of an interpreter and the interpreter’s identity will be documented on 
the electronic consent.  
12.4.  Continuing Consen t 
Subjects for whom consent was initially obtained from a LAR, but who subsequently regain decision- making capacity while in the hospi[INVESTIGATOR_307], will be approached for consent for continuing 
participati on, including continuance of data acquisition. The consent form signed by [CONTACT_274429] 
12.5.  Withdrawal of Consent  
Patients or the LAR may withdraw or be withdrawn (by [CONTACT_55639]) from the trial at any time without prejudice. Data recorded up to the point of withdrawal will be included in the trial 
analysis, unless consent to use their data has also been explicitly withdrawn. If a patient or LAR 
requests termination of study procedures during the treatment period, the procedures will be stopped but the patient will continue to be followed up as part of the trial. If a patient or LAR withdraws consent during trial treatment, the study procedures will be stopped but permission will be sought to access medical records for data related to the trial. If a patient or LAR wishes 
to withdraw from the trial after completion of trial treatment, permission to access medical records for trial data will be assumed unless explicitly withdrawn.   
12.6.  Identification of Legally Authorized Repre sentatives  
Many of the patients approached for participation in this research protocol will often have 
limitations of decision -making abilities due to their critical illness. Hence, some patients will not 
be able to provide informed consent.  Accordingly, informed consent will be sought from the potential subject’s legally authorized representative (LAR).   
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        41 
 Regarding proxy consent, the existing federal research regulations (‘the Common Rule’) states 
at 45 CFR 46.116 that “no investigator may involve a human being as a subject in 
research…unless the investigator has obtained the legally effective informed consent of the 
subject or the subject’s legally authorized representative”; and defines at 45 CFR 46 102 (c) a 
legally authorized representative (LAR) as “an individual or judicial or other body authorized under applicable law to consent on behalf of a prospective subject to the subject’s participation in the procedures(s) involved in the research.” The Office of Human Research Protections 
(OHRP) defined examples of “applicable law” as being state statutes, regulations, case law, or 
formal opi[INVESTIGATOR_1101] a State Attorney General that addresses the issue of surrogate consent to medical procedures. Such “applicable law” could then be considered as empowering the LAR  to 
provide consent for subject participation in the research. Interpretation of “applicable law” may 
be state specific and will be addressed by [CONTACT_274430].  
According to a previous President’s Bioethics Committee (National Bioethics Advisory 
Com mittee (NBAC)), an investigator should accept a relative or friend of the potential subject 
who is recognized as an LAR for purposes of clinical decision making under the law of the state 
where the research takes place [28]. Finally, OHRP has stated in their determination letters that 
a surrogate could serve as a LAR for research decision making if such an individual is 
authorized under applicable state law to provide consent for the “procedures” involved in the 
research study [29].      
12.7.  Justification of Surrogate Consent 
According to the Belmont Report, respect for persons incorporates at least two e thical 
convictions; first, that individuals should be treated as autonomous agents, and second, that 
person with diminished autonomy are entitled to protection. One method that serves to protect 
subjects is restrictions on the participation of subjects in research that presents greater than 
minimal risks. Commentators and research ethics commissions have held the view that it is 
permissible to include incapable subjects in greater than minimal risk research as long as there is the potential for beneficial effects and that the research presents a balance of risks and expected direct benefits similar  to that available in the clinical setting [30]. Several U.S. task 
forces have deemed it is permissible to include incapable subjects in research. For example, the American College of Physicians’ document allows surrogates to consent to research involving incapable subjects only  “if the net  additional risks of participation are not substantially greater 
than the risks of standard treatment.” [31]. Finally, NBAC stated that an IRB may approve a 
protocol that presents greater than minimal risk but offers the prospect of direct medical benefits 
to the subject, provided that “the potential subject’s LAR gives permission…” [28] 
Consistent with the above ethical sensibilities regarding the participation of decisionally incapable subjects in research and the previous assessment of risks and benefits in the 
previous section, the present trial presents a balance of risks and potential direct benefits that is 
similar  to that available in the clinical setting, with the exception of the additional blood draws.     
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        42 
 12.8.  Additional Safeguards for Vulnerable Subjects  
The present research will involve subjects who might be vulnerable to coercion or undue 
influence. As required in 45CFR46.111 (b), we recommend  that sites utilize additional 
safeguards to protect the rights and welfare of these subjects. Such safeguards might include, 
but are not limited to: a) assessment of the potential subject’s capacity to provide informed 
consent, b) the availability of the LAR to monitor the subject’s subsequent participation and 
withdrawal from the study; c) augmented consent processes. The specific nature of the 
additional safeguards will be left to the discretion of the central IRB, in conjunction with the sites.   
12.9.  Confidentiality  
Federal regulations at 45 CFR 46 111 (a) (7) requires that when appropriate, there are 
adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data. 
To maintain confidentiality, all laboratory specimens, evaluation forms, and reports will be 
identified only by a coded number.  The coded number will be generated by a computer, and 
only the study team will have access to the codes.  All records will be kept in a locked, 
password protected computer.  All computer entry and networking programs will be done with 
coded numbers only.  All paper case report forms will be maintained inside a locked office.  
Study information will not be released without the written permission of the patient, except as 
necessary for monitoring by [CONTACT_572], Lung, and Blood Institute, and the PETAL 
Clinical Coordinating Center.  
13. Adverse Events  
13.1  Safety Monitoring  
Assuring patient safety is an essential component of this protocol. Each participating 
investigator has primary responsibility for the safety of the individual participants under 
his or her care. The Investigators will determine daily if any adverse events occur during 
the period from enrollment through study day 6  (five days after completion of the study 
fluid protocol) or Hospi[INVESTIGATOR_2345], whichever occurs first.   
The following adverse events will be collected in the adverse event case report forms:  
 Serious adverse events  
 Non-serious adverse events that are considered by [CONTACT_274431] (Appendix G ) 
A clinical trial adverse event is any untoward medical event associated with study procedures, whether or not  it is considered related to the study procedures.   
After randomization, adverse events must be evaluated by [CONTACT_093]. If the adverse event is judged to be reportable, as outlined above, then the investigator will report to the CCC their assessmen t of the potential relatedness of each adverse event to protocol procedure via 
electronic data entry. Investigators will assess if there is a reasonable possibility that the study procedure caused the event, based on the criteria outlined in Appendix G. Investigators  will also 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        43 
 consider if the event is unanticipated or unexplained given the patient’s clinical course, previous 
medical conditions, and concomitant medications.   
Determining whether a treatment is causally related to the development of increased  oxygen 
requirements is a challenge, as it is difficult for a clinician to reliably discern hydrostatic from 
non-hydrostatic pulmonary edema.   Furthermore, increased hypoxia and/or need for additional 
respi[INVESTIGATOR_274356] ( eg early phases of ARDS) or a fluid 
bolus and this is also difficult to discern.   We will not consider the study endpoints of use of 
high- flow nasal cannula, non- invasive ventilation, or endotracheal intubation as AEs unless the 
events are judged by [CONTACT_274432] (see Appendix G2).   
If a patient's treatment is discontinued as a result of an adverse event, study site personnel 
must report the circumstances and data leading to discontinuation of treatment in the adverse event case report forms.   
13.[ADDRESS_335429] alert the CCC of any serious and study procedure related adverse event 
within 24 hours of investigator awareness of the event.  Alerts issued via telephone are to be 
immediately followed with official notification on the adverse event case report form. See 
Appendix G  for reporting timelines for serious, unexpected, study related events (SAEs) and 
serious, unexpected suspected adverse reactions (S[LOCATION_003]Rs) 
As per the FDA and NIH definitions, a serious adverse event is any adverse event that results in 
one of the following outcomes:  
 Deaths  
 A life -threatening experience (that is, immediate risk of dying)  
 Prolonged inpatient hospi[INVESTIGATOR_257353]- hospi[INVESTIGATOR_274357]://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm : Report if 
admission to the hospi[INVESTIGATOR_274358] a result of the adverse event. Emergency room visits that do not result in admission to the hospi[INVESTIGATOR_274359] (e.g., life- threatening; required intervention to prevent 
permanent impairment or damage; other serious medically important event).  
 Persistent or signif icant disability/incapacity  
As per http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm
: Report if the 
adverse event resulted in a substantial disruption of a person's ability to conduct normal life 
functions, i.e., the adverse event resulted in a significant, persistent or permanent change, 
impairment, damage or disruption in the patient's body function/structure, physical activities 
and/or quality of life.  
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335430], regardless of the investigator's opi[INVESTIGATOR_25289]. Thereafter, serious 
adverse events are not required to be reported unless the investigator feels the events were 
related to either study drug or a protocol procedure. 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        45 
 Appendices  
A. Protocol Schema   
 

CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        46 
 A.1 Liberal Protocol (follow for 24 hours)  
 

CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        47 
  A.2 Restrictive Protocol (follow for 24 hours)  
 
         
 
  
Rescue Fluids Recommended  
Does patient meet the following?  
 MAP < 65 mmHg or 
 SBP < 90 mmHg  
 
Titrate  norepi[INVESTIGATOR_274360]> /=65 
AAdd second  
vasopressor if needed  
 YES NO 
Reassess after 
intervention  Reassess 
within 1 hour  Rescue Fluids  Recommended 
500 cc IVF bolus allowed for any of the following:  
 Sever e hypotension  (< 70 mmHg  or MAP < 50 
mmHg ) 
 Refractory hypotension ( SBP<90 or MAP<65) 
with norepi [INVESTIGATOR_136] B20mcg/ min or equivalent dose of  
another vasopressor  
 Lactate > 4 mmol/l and rising  after 2 hours of 
therapy  
 Sinus heart rate >130 bpm for >  15mins  
 CEcho/hemodynamic evidence of extreme  
hypovolemia  
 Rescue fluids may be administered at any time if 
the clinical team believes that it is in the best 
interest of the patient  
 
Rescue fluids recommended : 
consider 500 cc boluses  YES Continue to Limit 
fluids  to 
KVO/m eds/nutrition SBP < 100  mmHg  or MAP <65  mmHg  after 1 -3 liters 
crystalloid  
Start Restrictive  protocol : 
1. Halt all bolus and maintenance fluids  
2. Administration of fluid boluses to up to 2 liters of total 
fluid, including pre -randomization fluid at the discretion 
of the clinical team without meeting “rescue fluid” criteria  
AEpi[INVESTIGATOR_274361], but not mandated, as second vasopressor  
B Norepi[INVESTIGATOR_238] 20mcg/min or 0.25 mcg/kg/min  
C Defined as: m aximal IVC diameter < 5mm; or  Empty left ventricle on echo (e.g. left -ventricular end -diastolic area  
 index < 5.5 cm2/m2 BSA) or  Substantial volume responsiveness defined as stroke volume increase > 30% in  
 response to a passive leg raise, fluid challenge, or positive pressure bre aths 
 
 Return to  care without study guidance  for 
the following:  
1. Suspi[INVESTIGATOR_274342] (e.g. bowel) or 
peripheral (e.g. limb or digit) ischemia or 
presence of mottling  
2. > [ADDRESS_335431] to:  
 Review of adverse events  
 Interim results of the study for evidence of efficacy or adverse events  
 Possible early termination of the trial because of early attainment of study objectives, 
safety concerns, or inadequate performance  
 Possible modifications in the clinical trial protocol  
 Performance of individual centers  
Two interim analyses will be conducted at approximately 33% and 66% target enrollment 
accrual.  
The NHLBI PETAL Network DSMB is appointed by [CONTACT_25513], NHLBI and makes 
recommendations to the NHLBI Director. The DSMB reviews all protocols for safety following 
review by [CONTACT_274433]. The DSMB will consist of members with expertise in acute lung injury, emergency medicine, biostatistics, ethics, and clinical trials. An NHLBI staff member not associated with PETAL will serve as Executive Secretary. Appointment of all members is contingent upon the absence of any conflicts of 
interest. All the members of the DSMB are voting members. The Principal Investigator [INVESTIGATOR_274362]. The DSMB will develop a charter and review the protoc ol and sample consent form during its first meeting. Subsequent DSMB meetings will be 
scheduled in accordance with the DSMB Charter with the assistance of the CCC. When 
appropriate, conference calls may be held in place of face -to-face meetings. Recommendations 
to end, modify, or continue the trial will be prepared by [CONTACT_274434], NHLBI. Recommendations for major changes, such as stoppi[INVESTIGATOR_007], will be reviewed by [CONTACT_274435]. Other recommendations will be reviewed 
by [CONTACT_274436], which will distribute to the PETAL steering committee with instructions for reporting to local IRBs when appropriate.  
Details of the NHLBI policies regarding DSMBs c an be found at the following URL: 
http://www.nhlbi.nih.gov/funding/policies/dsmb_inst.htm
   
The PETAL Network Steering Committee is comprised of the Principal Investigators and Co-
investigators of all the Clinical sites, the CCC, and the NHLBI Project Officer who represents the 
NHLBI.  All sites have two votes and the CCC has one.   
 
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335432] 12 hours since enrollment in the trial.  
2. FiO
2 ≤ 0.40 and PEEP ≤ 8 cm  
3. Values of both PEEP and FiO 2 ≤ values from previous day (comparing Reference 
Measurement values, section 6.3).  
 
Spontaneous breathing trial (SBT) procedure and assessment for unassisted breathing  
If criteria [ADDRESS_335433] the neuromuscular blocking agent will need to be discontinued 
if the medication is still being infused. When the neuromuscular blocking agent has worn off and 
the patient is having spontaneous respi[INVESTIGATOR_1520], then initiate a  trial of up to 120 minutes of 
spontaneous breathing with F IO2 < 0.5 using any of the following approaches:  
1. Pressure support < 5cm H 2O, PEEP < 5cm H 2O 
2. CPAP < 5 cm H 2O  
3. T-pi[INVESTIGATOR_13959] 
4. Tracheostomy mask  
Monitor for tolerance using the following:  
1. SpO 2 ≥ 90% and / or PaO 2 ≥ 60 mmHg 
2. Mean spontaneous tidal volume ≥  4 ml / kg PBW (if measured)  
3. Respi[INVESTIGATOR_13581] ≤ 35 / min 
4. pH ≥ 7.30 (if measured)  
5. No respi[INVESTIGATOR_1506] (defined as 2 or more of the following):  
a. Heart rate ≥ 120% of the 0600 rate (≤ 5 min at > 120% may be tolerated)  
b. Marked use of accessory muscles  
c. Abdominal paradox  
d. Diaphoresis  
e. Marked subjective dyspnea.  
If any of the goals 1- 5 are not met, revert to previous ventilator settings or to PS + 10 cm H 2O 
with Positive End -expi[INVESTIGATOR_274363] 2 = previous settings and reassess for weaning 
the next morning.  
The clinical team may decide to change mode of support during spontaneous breathing (PS = 5, 
CPAP, tracheostomy mask, or T- pi[INVESTIGATOR_13959]) at any time.  
Decision to remove ventilatory support  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        51 
 For intubated patients, if tolerance criteria for spontaneous breathing trial (1- 5 above) are met 
for at least 30 minutes, the clinical team may decide to extubate.  However, the spontaneous 
breathing trial can continue for up to120 minutes if tolerance remains in question. If any of 
criteria 1 -5 are not met during unassisted breathing (or 120 minutes has passed without clear 
tolerance), then the ventilator settings that were in use before the attempt to wean will be restored and the patient will be reassessed for w eaning (see section D.2) the following day.  
 Definition of unassisted breathing  
a) Extubated with face mask, nasal prong oxygen, or room air, OR  
b) T-tube breathing, OR  
c) Tracheostomy mask breathing, OR  
d) CPAP ≤ 5 without PS or IMV assistance  
e) Use of CPAP or BIPAP solely for sleep apnea management  
f) Use of a high flow oxygen system  
  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        52 
 E. Vasopressor Weaning  
1. When MAP > 65 mmHg on a stable dose of vasopressor, begin reduction of the 
vasopressor by [CONTACT_55559]  25% of the stabilizing dose at intervals of less 
than or equal to 4 hours to maintain  MAP greater than or equal to 65 mmHg.  
2. Dopamine is considered “discontinued" for vasopressor use and cell assignment when it 
is weaned to less than or equal to 5 mcg/kg/ min, but should continue to be weaned per 
protocol.  
 
Norepi[INVESTIGATOR_274364] : 
• norepi[INVESTIGATOR_238] 1 mcg/min    
• phenylephrine 2.5 mcg/min    
• epi[INVESTIGATOR_238] 1 mcg/min          
• vasopressin at any dose   
 
 
  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        53 
 F. Time Events Schedule  
Measurement/Event  Baseline  (0-6 
hrs) (6-24 
hrs) 1 2 3 4 5 6 7 28 90 
Demographics, History and Physical  X            
Vital Signs  X    X        
Vasopressor use X X X X X X       
Fluid Administration  X X X          
O2, non- invasive and invasive ventilation  X X          
Daily Fluid Balance (intake and output)     X X X X X X X   
Charlson Score X            
GCS  X   X X X       
Laboratory/microbiology results  A   A A A       
Diuretic use    X X X X X X X   
ARDS assessment  X   X X X X X X X   
Plasma Collection X   X  X       
DNA/RNA  X   X  X       
Plasma for IL- 6 and banking X   X  X       
Disposition           X  
Ventilator, Vasopressor, Renal 
replacement therapy use   
         X  
Assessment of infection source           X  
Vital Status            X X 
X=Required    
A=When available    
 
 
  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        54 
 G. Adverse Event Reporting and Unanticipated Events  
As noted in section 11.2, investigators will report all adverse events that are serious and study 
procedure related  (or of uncertain relatedness) to the CCC within [ADDRESS_335434] (cIRB) 
The Medical Monitor at the CCC will work collaboratively with the reporting investigator to 
determine if a serious adverse event has a reasonable possibility of having been caused by [CONTACT_161473], as outlined in 21 CFR 312.32 (a)(1)I, and below. The Medical Monitor will also 
determine if the event is unexpected. An adverse is considered “unexpected” if it is not l isted in 
the study protocol (21 CFR 312.32(a)). If a determination is made that a serious adverse event 
has a reasonable possibility of having been caused by [CONTACT_161473], it will be classified as a suspected adverse reaction.  If the suspected adverse reaction is unexpected, it will be 
classified as a serious unexpected suspected adverse reaction (S[LOCATION_003]R).   
The CCC will report all unexpected deaths, serious and treatment related adverse events, and 
S[LOCATION_003]Rs to the DSMB, NHLBI, and cIRB within 7 days after receipt of the report from a clinical 
site. A written report will be sent to the NHLBI, DSMB and the cIRB within 15 calendar days.  
The DSMB will also review all adverse events and clinical outcomes during scheduled interim analyses. If the DSMB deter mines that the  overall rate of adverse events is higher in one fluid 
protocol group, the cIRB will be notified within 15 days of this determination. The CCC will 
distribute the written summary of the DSMB’s periodic review of adverse events to the cIRB in 
accordance with NIH guidelines (http://grants.nih.gov/grants/guide/notice -files/not99- 107.html
). 
G1.  Unanticipated problems (UP)  
Investigators must also report Unanticipated Problems, regardless of severity, associated with 
study procedures within 24 hours. An unanticipated problem is defined as follows: any incident, 
experience, or outcome that meets all of the following criteria: 
 Unexpected, in terms of nature, severity, or frequency, given the research 
procedures that are described in the protocol -related documents, such as the IRB-
approved research protocol and informed consent document; and the characteristics of the subject population being studied;  
 Related or possibly related to participation in the research, in this guidance document, possibly related means there is a reasonable possibility that the incident, 
experience, or outcome may have been caused by [CONTACT_32015];  
 Suggests that the research places subjects or others at a greater risk of harm (including physical, psychological, economic, or social harm) than was previously 
known or recognized.  
G2.  Determining relationship of adverse events to pro cedures  
Investigators will be asked to grade the strength of the relationship of an adverse event to study 
procedures as follows:  
 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        55 
 • Definitely Related: The event follows: a) A reasonable, temporal sequence from a study 
procedure; and b) Cannot be explained by [CONTACT_11564]’s clinical 
state or other therapi[INVESTIGATOR_014]; and c) Evaluation of the patient’s clinical state indicates to the investigator that the experience is definitely related to study procedures.  
 
• Probably or Possibly Related: The event should be assessed following the same criteria for 
“Definitely Associated”. If in the investigator’s opi[INVESTIGATOR_274365], then “probably” or “possibly” associated should be selected.  
 
• Probably Not Related: The event occurred while the patient was on the study but can reasonably be explained by [CONTACT_11564]’s clinical state or other therapi[INVESTIGATOR_014].  
 
• Definitely Not Related: The event is definitely produced by [CONTACT_102]’s clinical state  or by 
[CONTACT_274437].  
. 
• Uncertain Relationship: The event does not meet any of the criteria previously outlined.  
 
G3.  Clinical outcomes that may be exempt from adverse event reporting 
Study -specific clinical outcomes of sepsis, as outlined in Sections 3.8.1 and 3.8.2 (Primary and 
Secondary Outcomes) and Section 6.3 (Assessments During the Study) are exempt from 
adverse event reporting unless the investigator deems the event to be related to the study procedures (or of uncertain relationship) or if the event leads to discontinuation of study 
procedures. The following are examples of events that will be considered study specific clinical outcomes  
• Death not related to the study procedures.   
• Cardiovascular events:   need for vasoactive drugs or fluids for hypotension or 
hypotension, Supraventricular/ventricular tachycardia (SVT) or new onset 
atrial fibrillation (AF). The occurrence of one or more epi[INVESTIGATOR_1841] (sustained for 
more than 1 minute for SVT and AF) during the hospi[INVESTIGATOR_274366].  
• Respi[INVESTIGATOR_29343]: decreased PaO 2/FiO2, hypoxia, worsening acute 
respi[INVESTIGATOR_1505], or respi[INVESTIGATOR_1399].  
• Hepatic events: hepatic injury or liver dysfunction that leads to an increase 
from baseline in the serum level of bilirubin.  
• Renal events: renal failure, renal insufficiency, or renal injury that leads to an increase from baseline in serum creatinine.  
• Hematologic/coagulation events: coagulopathy, disseminated intravascular coagulation, thrombocytopenia,  or thrombocytosis.  
Note: Arrhythmias such as heart block or ventricular fibrillation are not considered study specific 
clinical outcomes and should be recorded as adverse events if they are serious events or are 
considered by [CONTACT_274432].   
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        56 
 G4.  Decision tree for determining if an adverse event is reportable  
 
 
 
 
 
 
 
 
  
 
 
Adapted from Ranieri VM, Thompson BT, Barie PS et al. Drotrecogin alfa (activated) in adults 
with septic shock . N Engl J Med. 2012 May 31;366 (22):2055 -64. Epub 2012 May 22. PubMed 
PMID: 226168  
 
  

CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        57 
 H. Imputed P/F using SpO2 and FiO2  
The equivalence table below determines the estimated P/F ratio from the FiO2 and SpO2. This 
data was generated by [CONTACT_274438], on a cohort of critically ill patients 
with pneumonia [32-38]. 
 
For altitude adjustment, we will incorporate the practice from prior ARDS Network studies of using average ambient to sea level barometric pressure (for Utah, 0.86; for Denver, 0.84).  
Additional requirements for the use of the S/F ratio include: 
1. SpO
2 between 80- 96% 
2. SpO [ADDRESS_335435] 10 minutes after any change in FiO 2. 
3. PEEP ≥ 5 cm H 2O 
4. An adequate pulse oximeter waveform tracing  
 
 
 
 
 

CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        58 
 I. Language Cassettes Related to Provider Treatment Preference for the  
CLOVERS Treatment Recommendations  
Protocol elements  
• Subject recruitment plan and consent process:  
Study staff will identify potential study participants, confirm that the attending physician 
agrees that the study patient and/or family can be approached for consent.  
• Study procedures – Screening for eligibil ity:   
The attending physician of each patient eligible for inclusion will be contact[CONTACT_274439] a standardized script. The attending 
physician’s decision will be documented in the case report forms as  follows:  Attending 
physician 1) agrees both CLOVERS arms are consistent with good medical care 2) Does 
not agree 3) Does not have the time to consider this question.  Responses 2 or 3 will 
exclude the patient from participation  
• Patient recruitment - Standardized approach and script to be used to seek 
permission from attending physician to recruit a patient:  
For each patient who is potentially eligible for the trial, the CLOVERS site investigator or 
coordinator will contact [CONTACT_102]’s attending physician, with expertise in emergency or 
critical care medicine, and use the following script:  
 
“Dr. <name>, I am calling to seek your permission to approach your patient, 
<name>, for  
consent to participate in the CLOVERS  trial. This is an NIH -funded  trial that 
enrolls patients with early septic shock who have received one to three liters of fluid.  I am required to ask you if both of the CLOVERS treatment 
recommendations are consistent with good medical care for your patient.   
 
According to the protocol, those randomized to the restrictive arm will receive a 
vasopressor (we recommend norepi[INVESTIGATOR_238]) if your patient is still hypotensive after randomization. Additional fluids are recommended if the norepi[INVESTIGATOR_274367] 20 mcg/min, is ineffective (rising lac tate, refractory hypotension, 
ischemia or mottling) or poorly tolerated (heart rate over 130). Those assigned to the liberal arm will receive a 2 liter infusion of crystalloid (we recommend lactated 
ringers or Plasmalyte) over up to 3 hours if still hypotensive after randomization and as tolerated.  Additional 500 ml boluses are recommended for a systolic 
blood pressure < 90, oliguria, sinus tachycardia over 110, or indications of fluid 
responsiveness. Vasopressors are recommended for persistent hypotension 
(SBP < 70), lactic acidosis, or fluid overload.  In both arms, fluids or vasopressors 
can be used at any time if you feel they are in the best interest of the patient.  
Patients can be withdrawn from the protocol if clinical circumstances change and adher ence to the protocol places the patient at risk.  
 
We want to confirm that <name> is an appropriate candidate for the CLOVERS 
trial; and that in your clinical judgement both the restrictive and liberal fluid arms 
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335436] of the patient. ” 
 
This first two paragraphs will be used the initial time the trial team contacts the physician 
but could be skipped if the physician is already familiar with the protocol. The third 
paragraph will be stated when contact[CONTACT_274440].  Patients 
will only be approached for consent if their physician confirms his/her belief that either 
management strategy is appropriate, per the third paragraph.  
 Exposure of attending and nursing staff to CLOVERS protocol training in both the 
Emergency Departments and Intensive Care Units will be documented in the study 
binder at each CLOVERS hospi[INVESTIGATOR_307].  
 
  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        60 
 J. SHAMROC Study Protocol  
Title: SHAMROC: Sepsis -induced Hypotension: Assessing effect of Method of 
Resuscitation On patient -Centered outcomes  
STATEMENT OF HYPOTHESIS AND SPECIFIC AIMS  
Optimal resuscitation strategies for patients with sepsis -induced hypotension have been 
debated for decades. Critical questions are (a) whether to rely primarily on intravenous fluids 
(versus vasopressors), (b) how to optimally titrate the volume of fluid administered, and (c) whether vasopressors should be started earlier to spare the patient from large volumes of fluid. These key questions are relevant to hundreds of thousands of critically ill patients every year. Cross -national practices vary widely. Because individual clinicians hold strong opi[INVESTIGATOR_274368], observational studies remain hopelessly confounded by [CONTACT_35151]. Only randomization 
can persuasively disentangle the effects of strategies favoring fluids versus vasopressors.  
The Crystalloids Liberal Or Vasopressors Early Resuscitation in Sepsis (CLOVERS) trial is a 
large (n=2,320) nationwide multi- center randomized clinical trial by [CONTACT_15792] -sponsored 
PETAL network to test whether an early “wet” fluid- intensive/pressor -restrictive strategy 
improves 90- day in- hospi[INVESTIGATOR_274322] -induced hypotension, compared to 
an early “dry” fluid -restrictive/pressor -intensive strategy. CLOVERS presents a unique and 
fleeting opportunity to definitively measure patient- centered outcomes caused by [CONTACT_274441]. CLOVERS will enroll over 3 years, starti ng March 2018.  
The pragmatic CLOVERS design focuses on hospi[INVESTIGATOR_95209]. Thus, CLOVERS will not 
address key patient -centered controversies that are prominent in the literature:  
Cognitive Impairment : An ancillary study of the NHLBI -funded Fluid and Catheter Treatment 
Trial (FACTT) showed that randomization to a dry strategy in patients with ARDS was 
associated with impaired memory, verbal fluency, and executive functioning—with a quadrupling 
of the odds of cognitive impairment (71% cognitively impaired vs 38%, OR: 4.0 (95% CI: 1.5 –
10.6)) despi[INVESTIGATOR_274369] -hospi[INVESTIGATOR_34380] —but, in a sample of just 75 survivors of ARDS, not 
all with sepsis. 
Physical Disability: Observational analyses suggest that net fluid balance at ICU discharge is 
a determinant of subsequent mobility and ability to return home. Simplistically, edema increases the work required to move and contributes to stiffness, pain, and impaired balance. More subtly, aggressive fluid resuscitation may lengthen mechanical ventilation due to pulmonary  edema, 
and the ventilator itself may be a driver of systemic inflammation. This combination of inactivity, inflammation, and risk for complications could lead to prolonged institutional care and 
subsequent disability. Existing data are inconclusive.  
Impor tantly, the prior literature suggests that a wet strategy may be superior for some outcomes 
(eg, better cognitive function), but a dry strategy may be superior for other outcomes ( eg, 
decreasing disability). Patients and clinicians want individualized information about cognitive 
and disability outcomes to make treatment choices. But —because wet versus dry fluid 
strategies may affect these outcomes differently —we must measure these outcomes directly to 
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335437]. Sepsis -induced Hypotension: Assessing effect of Method of 
Resuscitation On patient Centered outcomes (SHAMROC) study prospectively measures 
outcomes in an estimated 1,420 surviving CLOVERS participants not already profoundly 
cognitively impaired or disabled prior to randomization.  
AIM 1: Test the hypothesis that randomization to dry resuscitation for sepsis -induced 
hypotension results in worse cognitive impairment at 6 and 12 months compared to wet 
resuscitation.  Survivors will undergo treatment -blinded centralized telephone assessment  of 
overall cognitive function (Montreal Cognitive Assessment, the MoCA -Blind) and specifically 
executive function (Hayling Sentence Completion Test). 
Aim 1b: Test the hypotheses that differences are mediated by (a) days of mechanical 
ventilation, (b) seve rity of hypoxemia, or (c) rates of acute renal failure.  
AIM 2: Test the hypothesis that randomization to wet resuscitation for sepsis -induced 
hypotension results in worse physical disability at 6 and 12 months compared to dry 
resuscitation.  Survivors will undergo treatment -blinded centralized telephone assessment of 
overall physical disability (activities and instrumental activities of daily living (I/ADLs), using the functional limitations survey from the Health and Retirement Study) and of mobility and st rength 
(10 Items from the NIH PROMIS Mobility Bank).  
Aim 2b: Test the hypotheses that differences are mediated by (a) net fluid balance, (b) days of 
mechanical ventilation, or (c) rates of acute renal failure.  
AIM 3: Test the hypothesis that the net benefit of randomization to wet versus dry 
resuscitation on cognitive impairment and on physical disability will vary across individual patient’s baseline risk for these outcomes.  We will develop de novo risk scores in 
this trial for the specific purposes of both qualitatively and quantitatively testing for clinically 
meaningful differences in responses to wet versus dry resuscitation.  
BACKGROUND  
It is important for interventional trials to look for outcomes beyond mortality. Decades ago, Fried 
and colleagues demonstrated that patients and families value functional independence and cognitive outcomes more highly than survival- at-any-cost. (3) However, most studies of critical 
care interventions are designed only to look at mortality outcomes, including CLOVERS.  
There are compelling arguments why resuscitation strategy might causally impact long-term outcomes other than mortality. Mikkelsen and colleagues conducted a secondary analysis on a 
subgroup of the ARDS Network FACTT investigation of fluid management after resolution of 
shock which suggested that a fluid restrictive strategy may be causally associated with cognitive 
impairment, particularly in domains of executive function, verbal fluency and memory. (1, 2) This 
study, along with additional observational work, raises the concern that the fluid restrictive arm 
of CLOVERS could place patients at risk for impaired cognitive function.  
However, the converse could also be true— perhaps a fluid liberal resuscitation strategy is 
associated with poorer outcomes.  There are compelling observational data directly and 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        62 
 indirectly suggesting that volume overload is associated with physical functional impairment. For 
example, significant volume overload at ICU discharge in patients with septic shock is independently associated with inability to walk at the time of hospi[INVESTIGATOR_2345], and lower 
likelihood of discharging home (as opposed to continued post-hospi[INVESTIGATOR_274370]). (4) It is 
clear that fluid liberal strategies are associated with prolonged mechanical ventilation, which, in 
turn, is strongly associated with weakness and poorer functional outcome at hospi[INVESTIGATOR_274371]. (1, 5). 
In sum, o bservational data are inadequate in unraveling the relationship between resuscitation 
strategy and long- term outcomes, since indication bias and unmeasured confounders risk 
causal interpretation of potential associations. As such, CLOVERS represents a once- in-a-
lifetime opportunity to address key knowledge gaps, including: does initial resuscitation strategy 
impact cognitive outcomes and functional disability, and are there identifiable effect modifiers of 
this relationship? 
PRELIMINARY DATA 
Cognitive impairment and disability are common after sepsis, even among patients without 
impairment in the year prior to sepsis hospi[INVESTIGATOR_059]. ( 6) Simple instruments that can be reliably 
administered over the telephone can detect these impairments, both with patient and proxy participation. For example, in a subgroup of 269 patients in the Health and Retirement Study who had no limitations on pre -sepsis assessment of Individual or Instrumental Activities of Daily 
Living, sepsis hospi[INVESTIGATOR_274372] 1.57 new limitations. Similarly, accounting for pre -sepsis cognitive baseline, sepsis hospi[INVESTIGATOR_274373] a tripled 
odds of moderate/severe cognitive impairment using a t elephone- administered assessment.  
Endpoints  
There is one primary endpoint for Aim One: Cognitive Impairment as determined by [CONTACT_274442] -
Blind administered at 6 and 12 months after CLOVERS enrollment (or proxy -assessed 
equivalent measure).  
There is one primary endpoint for Aim Two: Disability as determined by [CONTACT_183271]/iADL, assessed via 
either patient or proxy.  
Study Design  
Inclusion/Exclusion Criteria  
Inclusion Criterion :   Enrolled in CLOVERS  
Exclusions:  
1. Severe premorbid cognitive impairment or disability (by [CONTACT_274443]8 and ADL/iADL at 
CLOVERS enrollment)  
2. Patient neither fluent in English nor Spanish  
3. Patient is homeless  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        63 
 Study Population & Enrollment  
SHAMROC is an ancillary study to the parent RCT of CLOVERS that will determine the effect of 
randomization arm  (resuscitation strategy) on cognitive impairment and disability measured [ADDRESS_335438] been taken to minimize the risks of this study. Even so, potential risks may include 
the following: patients may experience various emotions when responding to the interview questions. However, they may choose to skip any interview question they feel uncomfortable 
answering.   
Another risk is the possible loss of confidentiality of the interview responses. We believe that 
risk of a breach of confidentiality is low. Throughout the study, IRB and HIPAA guidelines will be 
followed to ensure the privacy and integrity of the information we collect.  
There may be other risks that are unforeseeable at this time.   
Data Collection  
Three categories of data will be needed for SHAMROC.  
1. Data collected for CLOVERS: Most needed data reflecting demographics, comorbidities, acute illness variables, data describing hospi[INVESTIGATOR_2779], and hospi[INVESTIGATOR_274374]. SHAMROC will obtain these data from the CCC. Additionally, we will need randomization assignments (after trial unblinding). Hospi[INVESTIGATOR_307] -course data will be obtained after CLOVERS is complete. Demographic, 
hospi[INVESTIGATOR_274375], destination of discharge, and contact [CONTACT_274444], as these data will be required for post -hospi[INVESTIGATOR_274376] -up. 
2. Data added to baseline assessment: In order to determine eligibility for SHAMROC, we will need to collect 5 additional data elements at the time of CLOVERS enrollment. These data points are encompassed in less than 25 simple questions which add 5 -10 
minutes of time to CLOVERS and will be compensated by [CONTACT_274445]. These data points include:  
a. Baseline cognitive screen (using the Alzheimer’s Disease 8, AD8) via an eight question survey designed for proxies  
b. Baseline disability (using the Individual and Instrumental Activities of Daily Living 
instruments, the same as is used in ROSE) via a thirteen question survey 
validated in proxies  
c. Current living situation (using the single item, same as in ROSE)  
d. Contact [CONTACT_3031], using the same data collection sheet as ROSE  
e. Language spoken by [CONTACT_102]  
3. Data will be collected during 6- and 12- month interviews: All eligible and surviving 
patients will be contact[CONTACT_274446], University of  Washington or 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        64 
 Oregon Health and Science University (OHSU will only contact [CONTACT_274447]), for participation in telephone assessment of cognitive function and disability. 
Subjects (or proxies if subjects unable to participate) will complete 7 instruments, for an 
estimated total call duration of 20- 30 minutes. Participants will be compensated for their 
time. Surveys will be conducted in English or Spanish, and include: 
a. Cognitive assessment: Montreal Cognitive Assessment -Blind (if patient 
participating) or AD8 (if proxy participating) (7-9) (10, 11 ) (12) 
b. Executive function assessment: Hayling Sentence Completion Test (patient only, 
no Spanish)  
c. EQ-5D-5L  
d. Disability assessment: ADL/iADL instrument (patient or proxy)  (13) (14) (15) 
e. Mobility assessment: PROMIS Mobility short form (patient or proxy) (16) 
f. Current living situation  
g. Recent healthcare use  
Each participant will receive a $[ADDRESS_335439] prior to the 6- and 12 -month interviews. Each participant will receive a $[ADDRESS_335440] a protocol to avert refusals, specifically an increase from the original $10 to $20. This increased amount is based on prior studies as well as advice with personnel at the University of Michigan Health and Retirement Study (HRS), launched in [ADDRESS_335441]. After gauging participation rates over 
the course of the study, study staff may find it necessary to offer an incentive of $[ADDRESS_335442] survey, we will then offer an additional 
incentive of $10 for a total of $20. Once a participant is offered the higher incentive, they will 
receive that amount for each of the remainder of surveys that they complete.  
In no case will more than $[ADDRESS_335443] in the literature. For example, Turnbull et al recently published a study with incentives up to $50, and Robinson et al’s recent systematic review 
noted studies with incentives up to $160.  
The interviewers have demonstrated their excellence with telephone administration of surveys 
and the central assessment of all long- term outcomes in the ROSE study (FUNCTION, led by 
[CONTACT_6283]. Jack Iwashyna and Mic Couper). Final survey completion rates were 88.5%, 85.5%, and 
84.8% at 3- , 6-, and 12 -months, respectively.  
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        65 
  
Statistical Considerations 
Sample size: CLOVERS has an anticipated sample size of 2320. We anticipate that no more 
than 20% will be ineligible due to severe pre- existing cognitive impairment or disability, 
languages other than English or Spanish (since CLOVERS consent is only being conducted in 
these two languages), or lack of telephone or permanent address, leaving 1856 potentially eligible for SHAMROC  analyses. As described in analytic plan below, note that patients who die 
before follow -up are retained in the analytic cohort.  
Primary Analysis for Aim 1: “Does randomization to different resuscitation strategies cause a difference in cognitive function,  unbiased by [CONTACT_274448]- based 
selection?” Differential mortality can lead to misleading analyses of the impact of treatment on 
outcomes. This has been termed “selection bias” (86), “informative censoring,” or “censoring of 
the extreme phenotype”. (87) There is no universally accepted solution to this problem. We 
propose the approach of Permutt and Li of  the Office of Biostatistics at the U.S. Food and Drug 
Administration and also endorsed by [CONTACT_274449] -sponsored review. (88) This approach 
recognizes that death is extremely poor cognitive function, just not assessed on the same numeric scale as the MoCA -Blind or HSCT. This approach will be used for the primary analysis 
using MoCA -Blind, and an executive function- specific secon dary analysis using HSCT.  
The method of Permutt and Li calculates an empi[INVESTIGATOR_173824] (ECDF) 
for the fraction of patients with cognitive impairment, considering all possible dichotomizations of the cognition scores (including informative non -response due to poor cognition and death as the 
most extreme forms of poor cognition).
  
Permutt and Li thereby [CONTACT_274450] a single cut -point ( ie, 
with the Rankin scale), while giving an interpretable summary statistic. Permutt and Li 
demonstrate that the mean 
outcome scores among the better performing patients from each study arm (“trimmed means”) are efficient statistics 
for reporting the between -group 
differences using the intention to treat principle. They recommend trimming each trial arm equally, 
just above the expected overall rate of death and non- response. In SHAMROC, 33% of each 
study arm will be “trimmed.”  Measuring Potential Mediators in SHAMROC.  
All will be collected as part of the CLOVERS CRF.  
Days of mechanical ventilation  in the first [ADDRESS_335444] 7 days. (Aims 1 & 2)  
Severity of hypoxemia will be measured as the lowest 
routinely obtained pulse oximetry saturation on the daily logs, 
obtained during the first 7 days in the ICU. (Aim 1)  
Renal failu re will be defined by [CONTACT_274451] 
(serum creatinine criteria only (89)) between baseline and [ADDRESS_335445] urine output, we will 
use only the creatinine criteria. (90) Patients on chronic 
dialysis will be ineligible for this analysis. (Aims 1 & 2)  
Net fluid balance  will be defined as a proportion change in 
body weight compared to admission, as in (18). (Aim 2) 
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335446] interpretation: “How large of a 
difference in average cognitive function is caused by [CONTACT_274452], measured in the better -off ⅔ of patients?” Perm utt and Li developed a 
permutation test for the confidence interval for this test statistic under no assumptions other than randomization, which is particularly appealing given the often -skewed distributions of 
cognitive function scores. We will report both the test statistic (with 95% CI) and graphically 
present the ECDF curve for each randomized group to summarize all data. 
If necessary due to missing data in the electronic case report form (CRF) —which is not 
expected—we will use a Bayesian implementation of the model to impute missing values nested 
within sites, using a Gibbs sampler to impute from the posterior of the missing data given 
observed data. (91-95)  
Mediation Analysis for Mechanism.  
We hypothesize that differences in cognitive outcome between wet and dry resuscitation may 
stem from differences in rates of intervening organ dysfunctions and hypoxia. Respi[INVESTIGATOR_274377], exposure to deliriogenic medications and practices, (96) or systemic effects of ventilator -induced lung injury. (97) Renal dysfunction may 
harm the brain by  [CONTACT_274453] (98) and multiple organ dysfunction, progression to 
chronic kidney disease, (99) uremia, or exposure to dialysis (“dialysis brain” or “hemodialysis 
fatigue syndrome” (100) ). Hypoxemia was a major independent predictor of poor outcome in 
ACOS. (11, 101, 102)   
To test mediation if there is a difference between treatment groups, we will generalize the primary analysis. Permutt and Li demonstrate that analysis of covariance (ANCOVA) can be used to estimate the trimmed mean test statistic, adjusting for a potential mediator. This is repeated on each of the permuted datasets to develop confidence intervals. This allows us to 
assess—one -by-one for each potential mediator —the magnitude of the difference in average 
cognitive function between wet and dry treatment arms  explained by [CONTACT_274454]. 
 
Analysis for Aim 2: “Does randomization to different resuscitation strategies cause a difference in physical disability, unbiased by [CONTACT_274448] -based selection?”  
Paralleling our approach in Aim 1, we will use the method of Permutt and Li to assess: “How 
large of a difference in average physical disability is caused by [CONTACT_274452], measured in the better -off two -thirds of patients?” Death will be considered as an 
extreme form of physical disability, and permutation tests will be used to calculate a confidence 
interval for this test statistic under no assumptions other than randomization. We will report both the test statistic (95% CI) and graphically present the ECDF curves by [CONTACT_196880]. 
Mediation Analysis for Mechanism. Similar to effects on cognitive impairment, we 
hypothesize that initial resuscitation strategy may affect disability outcomes through a number of 
key pathways. We will focus on respi[INVESTIGATOR_1399], renal failure, and persistent hypervolemia as potential mediating factors. Respi[INVESTIGATOR_274378] -ICU 
disability, with likely contributions from immobility, increased days of delirium/coma due to 
sedation, higher levels of inflammation, and longer duration of hospi[INVESTIGATOR_059]. Loss of muscle 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        67 
 mass, for example, is accelerated in patients with respi[INVESTIGATOR_274379] (115) . It is 
possible that acute respi[INVESTIGATOR_274380]. Renal  failure may differ 
between study arms and is another factor frequently associated with physical impairment after critical illness, with increased incidence of muscle loss and weakness.(115, 116)  The [ADDRESS_335447] 4 hours.  
Paralleling Aim 1, we will use Permutt and Li’s ANCOVA to answer: “How large of a difference 
in average physical disability is caused by [CONTACT_274452], 
measured in the better -off ⅔ of patients, controlling for differences in the hypothesized 
mediator?” We will also report the fractional reduction of the unadjusted effect that is associated 
with each hypothesized mediator. 
Analysis for Aim 3:  We hypothesize that the net benefit of wet versus dry resuscitation on 
cognitive impairment and physical disability will vary across individual patients, based on a 
patient’s baseline risk for these outcomes. To test whether the magnitude of this variation is 
clinically meaningful across patients, we will complete pre -specified sub- group analyses in 
which patients are stratified into tertiles of risk for cognitive impairment (and separately, by [CONTACT_274455]). In  addition, we will assess for HTE directly by [CONTACT_274456] 6- month outcome 
within a regression model. These two complimentary approaches to assessing and presenting HTE (risk -based subgroup analysis and an interaction term) are recommended as “best 
practices” for the testing and reporting HTE. (20)  
  
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335448] GR, Thompson BT, et al. Comparison of two fluid-
management strategies in acute lung injury. The New England journal of medicine. 
2006;354(24):2564 -75. doi: 10.1056/NEJMoa062200. PubMed PMID: 16714767.  
2. Mikkelsen ME, Christie JD, Lanken PN, Biester RC, Thompson BT, Bellamy SL, et al. 
The adult respi[INVESTIGATOR_129383] s syndrome cognitive outcomes study: long- term 
neuropsychological function in survivors of acute lung injury. American journal of respi[INVESTIGATOR_4447]. 2012;185(12):1307 -15. doi: 10.1164/rccm.201111- 2025OC. PubMed 
PMID: 22492988; PubMed Central PMCID: PMC3381234.  
3. Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of 
seriously ill patients. The New England journal of medicine. 2002;346(14):1061- 6. doi: 
10.1056/NEJMsa012528. PubMed PMID: 11932474.  
4. Mitchel l KH, Carlbom D, Caldwell E, Leary PJ, Himmelfarb J, Hough CL. Volume 
Overload: Prevalence, Risk Factors, and Functional Outcome in Survivors of Septic Shock. 
Annals of the American Thoracic Society. 2015;12(12):1837- 44. doi: 
10.1513/AnnalsATS.201504- 187OC . 
5. Herridge MS, Chu LM, Matte A, Tomlinson G, Chan L, Thomas C, et al. The RECOVER 
Program: Disability Risk Groups and 1 -Year Outcome after 7 or More Days of Mechanical 
Ventilation. American journal of respi[INVESTIGATOR_4447]. 2016;194(7): 831-44. doi: 
10.1164/rccm.201512 -2343OC. PubMed PMID: 26974173.  
6. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long- term cognitive impairment and 
functional disability among survivors of severe sepsis. Jama. 2010;304(16):1787 -94. PubMed 
PMID: 20978258.  
7. Hobson J. The Montreal Cognitive Assessment (MoCA). Occup Med (Lond). 
2015;65(9):764 -5. doi: 10.1093/occmed/kqv078. PubMed PMID: 26644445.  
8. Nasreddine ZS, Phillips N, Chertkow H. Normative data for the Montreal Cognitive 
Assessment (MoCA) in  a population- based sample. Neurology. 2012;78(10):765 -6; author reply 
6. doi: 10.1212/01.wnl.[PHONE_5694].[ZIP_CODE].a3. PubMed PMID: 22391608.  
9. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. 
The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. 
J Am Geriatr Soc. 2005;53(4):695- 9. doi: 10.1111/j.1532- 5415.2005.[ZIP_CODE].x. PubMed PMID: 
15817019.  
10. Christie JD, Biester RC, Taichman DB, Shull WH, Jr., Hansen- Flaschen J, Shea JA, et 
al. Formation and validation of a telephone battery to assess cognitive function in acute 
respi[INVESTIGATOR_274381]. J Crit Care. 2006;21(2):125- 32. doi: 
10.1016/j.jcrc.2005.11.004. PubMed PMID: 16769455.  
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335449], Welch SJ, Cuthbertson FC, Mariz J, Mehta Z, Rothwell PM. Telephone 
assessment of cognition after transient ischemic attack and stroke: modified telephone interview 
of cognitive status and telephone Montreal Cognitive Assessment versus face- to-face Montreal 
Cognitive Assessment and neuropsychological battery. Stroke. 2013;44(1):227 -9. doi: 
10.1161/STROKEAHA.112.673384. PubMed PMID: 23138443; PubMed Central PMCID: 
PMCPMC5593099.  
12. Wallace RB, Herzog AR, Weir DR, Ofstedal MB, Langa KM, Fisher GG, et al. 
Documentation of Cognitive Functioning Measures  in the Health and Retirement Study. Ann Arbor, MI: Survey Research Center, University of Michigan, 2005. 
13. Organization WH. The International Classification of Functioning, Disability and Health 
(ICF) Geneva: WHO; 2001. Available fr om: http://www.who.int/classifications/icf/en/
. 
14. Wallace RB, Herzog AR, Ofstedal MB, Fonda SJ, Steffick D, Langa KM, et al. 
Documentation of Physical Functioning Measured in the Heath and Retirement Study and the 
Asset and Health Dynamics among the Oldest Old Study Ann Arbor, MI: Survey Research 
Center, University of Michigan, 2004.  
15. Ahasic AM, Van Ness PH, Murphy TE, Araujo KL, Pi[INVESTIGATOR_99657]. Functional status after 
critical illness: agreem ent between patient and proxy assessments. Age Ageing. 
2015;44(3):506 -10. doi: 10.1093/ageing/afu163. PubMed PMID: 25324334; PubMed Central 
PMCID: PMCPMC4411220.  
16. Hays RD, Spritzer KL, Amtmann D, Lai JS, Dewitt EM, Rothrock N, et al. Upper -
extremity and mobility subdomains from the Patient -Reported Outcomes Measurement 
Information System (PROMIS) adult physical functioning item bank. Arch Phys Med Rehabil. 2013;94(11):2291 -6. doi: 10.1016/j.apmr.2013.05.014. PubMed PMID: 23751290; PubMed 
Central PMCID: P MCPMC3812258.  
17. Permutt T, Li F. Trimmed means for symptom trials with dropouts. Pharm Stat. 
2017;16(1):20 -8. doi: 10.1002/pst.1768. PubMed PMID: 27523396.  
18. Colantuoni E, Scharfstein DO, Wang C, Hashem MD, Leroux A, Needham DM, et al. 
Statistical meth ods to compare functional outcomes in randomized controlled trials with high 
mortality. BMJ. 2018;360:j5748. doi: 10.1136/bmj.j5748. PubMed PMID: 29298779.  
19. Cohen J. Statistical Power Analysis for the Behavioral Sciences 2nd ed. [LOCATION_001]: 
Lawrence Erlbaum Associates; 1988. 
20. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting 
heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85. doi: 
10.1186/1745 -6215- 11-85. PubMed PMID: 20704705; PubMed Central PMCID: PMC2928211.  
 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        70 
 References  
1. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R et al. Surviving 
Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017;45(3):486- 552. 
doi:10.1097/CCM.0000000000002255.  
 2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B et al. Early goal -
directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345(19):1368- 77. doi:10. 1056/NEJMoa010307.  
 3. Investigators P, Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA et al. A randomized trial of protocol -based care for early septic shock. N Engl J Med. 
2014;370(18):1683- 93. doi:10.
1056/NEJMoa1401602.  
 4. Investigators A, Gro up ACT, Peake SL, Delaney A, Bailey M, Bellomo R et al. Goal -
directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371(16):1496- 506. doi:10.1056/NEJMoa1404380.  
 5. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD et al. 
Trial of early, goal -directed resuscitation for septic shock. N Engl J Med. 
2015;372(14):1301- 11. doi:10.1056/NEJMoa1500896.  
 6. Lilly CM. The ProCESS trial--a new era of sepsis management. N Engl J Med. 2014;370(18):1750- 1. doi:10.1056/NE JMe1402564.  
 7. SJ L, K R, JG P, O G, G L, R K. Increased fluid administration in the first three hours of sepsis resuscitation is associated with reduced mortality: A retrospective cohort study. Chest. 2014;146:908- 15.  
 8. Nguyen HB, Jaehne AK, Jayaprakash N, Semler MW, Hegab S, Yataco AC et al. Early goal -directed therapy in severe sepsis and septic shock: insights and comparisons 
to ProCESS, ProMISe, and ARISE. Crit Care. 2016;20(1):160. doi:10.1186/s13054- 016-
1288- 3. 
 9. FORUM NQ. NQF #0500 Severe Sepsis and Septic Shock: Management Bundle. In: NQF #0500 Severe Sepsis and Septic Shock: Management Bundle. http://www.qualityforum.org/NQF_Revises_Sepsis_Measure.aspx
. 
 10. Hjortrup PB, Haase N, Bundgaard H, Thomsen SL, Winding R, Pettila V et al. 
Restricting volumes of resuscitation fluid in adults with septic shock after initial management: the CLASSIC randomised, parallel -group, multicentre feasibility trial. 
Intensive Car e Med. 2016;42(11):1695- 705. doi:10.1007/s00134- 016-4500- 7. 
 11. Marik PE. Iatrogenic salt water drowning and the hazards of a high central venous pressure. Ann Intensive Care. 2014;4:21. doi:10.1186/s13613- 014-0021- 0. 
 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        71 
 12. (CMS) CfMaMS. CMS to Improve Quality of Care during Hospi[INVESTIGATOR_274382]. In: 
(CMS) CfMaMS, editor.2014.  
 13. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C et al. Comparison of dopamine and norepi[INVESTIGATOR_274383]. N Engl J Med. 2010;362(9):779- 89. doi:10.1056/NEJMoa0907118.  
 14. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580- 637. 
doi:10.1097/CCM.0b013e31827e83af.  
 15. Lewis RJ. Disassembling goal -directed therapy for sepsis: a first step. JAMA. 
2010;303(8):777- 9. doi:10.1001/jama.2010.203.  
16. Jones AE. Unbundling early sepsis resuscitation. Ann Emerg Med. 2014;63(6):654-5. doi:10.1016/j.ann emergmed.2013.10.034.  
 17. JA M, RS H, RM W, al e. Rosen’s Emergency Medicine: Concepts and Clinical Practice. Philadelphia: 2006.  
 18. Cardenas -Garcia J, Schaub KF, Belchikov YG, Narasimhan M, Koenig SJ, Mayo 
PH. Safety of peripheral intravenous administration of vasoactive medication. J Hosp Med. 2015;10(9):581- 5. doi:10.1002/jhm.2394.  
 19. Loubani OM, Green RS. A systematic review of extravasation and local tissue injury from administration of vasopressors through peripheral intravenous catheters and central venous catheters. J Crit Care. 2015;30(3):653 e9- 17. 
doi:10.1016/j.jcrc.2015.01.014.  
 20. Kelm DJ, Perrin JT, Cartin- Ceba R, Gajic O, Schenck L, Kennedy CC. Fluid 
overload in patients with severe sepsis and septic shock treated with early goal-directed 
therapy is associated with increased acute need for fluid- related medical interventions 
and hospi[INVESTIGATOR_39473]. Shock. 2015;43(1):68- 73. doi:10.1097/SHK.0000000000000268.  
 21. Hamzaoui O, Georger JF, Monnet X, Ksouri H, Maizel J, Richard C et al.  Early 
administration of norepi[INVESTIGATOR_274384] -threatening hypotension. Crit Care. 2010;14(4):R142. 
doi:10.1186/cc9207.  
 22. Monnet X, Marik P, Teboul JL. Passive leg raising for predicting fluid 
responsiveness: a systematic review and meta- analysis. Intensive Care Med. 
2016;42(12):1935- 47. doi:10.1007/s00134- 015-4134- 1. 
 23. Dong ZZ, Fang Q, Zheng X, Shi H. Passive leg raising as an indicator of fluid responsiveness in patients with severe sepsis. World J Emerg Med. 2012;3(3):191- 6. 
doi:10.5847/wjem.j.1920- 8642.2012.03.006.  
CLOVERS Protocol Version VIII  
February 17, [ADDRESS_335450] NJ, Eastwood GM, Bellomo R. Physiological changes after fluid bolus 
therapy in sepsis: a systematic review of contemporary data. Crit Care. 2014;18(6):696. doi:10.1186/s13054- 014-0696- 5. 
 25. Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC et al. Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care. 2 013;17(6):R278. 
doi:10.1186/cc13133.  
 26. Maitland K, Kiguli S, Opoka RO, Engoru C, Olupot -Olupot P, Akech SO et al. 
Mortality after fluid bolus in African children with severe infection. N Engl J Med. 2011;364(26):2483- 95. doi:10.1056/NEJMoa1101549.  
 27. LAN KKG, DEMETS DL. Discrete sequential boundaries for clinical trials. 
Biometrika. 1983;70:659- 63.  
 28. National Bioethics Advisory Commitee (NBAC). Research Involving Persons with Mental Disorders That May Affect Decisionmaking Capacity. Rockville: U.S.  
Government Printing Office; 1998.  
 29. Office of Human Research Protections (OHRP). Compliance Determination Letters. 2002. http://ohrp.osophs.dhhs.gov/detrm_letrs/
. 
 30. Dresser R. Research Involving Persons with Mental Disabilities: A Review of Policy Issues and Proposals.  National Bioethics Advisory Commission. Rockville: U.S. Government Printing Office; 1999. p. 5 -28. 
 31. American College of Physicians. Cognitively Impaired Subjects. Ann Int Me d. 
1989;111:843- 8.  
 32. Ellis RK. Determination of PO2 from saturation. Journal of applied physiology. 1989;67(2):902.  
 33. Rice T, Wheeler A, Bernard G, Hayden D, Schoenfeld D, Ware L et al. Comparison of the Sp02/FI02 Ratio and the PaO 2/FI02 in Patients with Acute Lung Injury or ARDS. Chest. 2007;132(2):410- 7.  
 34. Lanspa MJ, Jones BE, Brown SM, Dean NC. Mortality, morbidity, and disease severity of patients with aspi[INVESTIGATOR_59499]. J Hosp Med. 2013;8(2):83- 90. 
doi:10.1002/jhm.1996.  
 35. Severinghaus JW. Simple, accurate equations for human blood O2 dissociation computations. Journal of applied physiology: respi[INVESTIGATOR_696], environmental and exercise physiology. 1979;46(3):599- 602.  
 
CLOVERS Protocol Version VIII  
February 17, 2021                                                                                                                                                        73 
 36. Dean NC, Jones JP, Aronsky D, Brown S, Vines CG, Jones BE et al. Hospi[INVESTIGATOR_274385] -acquired pneumonia: variability among 
physicians in an emergency department. Ann Emerg Med. 2012;59(1):35- 41. 
doi:10.1016/j.annemergmed.2011.07.032.  
 37. Brown SM, Jones BE, Jephson AR, Dean NC, Infectious Disease Society of America/American Thoracic S. Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community -acquired 
pneumonia. Crit Care Med. 2009;37( 12):3010 -6. doi:10.1097/CCM.0b013e3181b030d9.  
 38. Van de Louw A, Cracco C, Cerf C, Harf A, Duvaldestin P, Lemaire F et al. Accuracy of pulse oximetry in the intensive care unit. Intensive Care Med. 2001;27(10):1606- 13. 
doi:10.1007/s001340101064.
 
 